




(86) Date de dépôt PCT/PCT Filing Date: 2011/09/16
(87) Date publication PCT/PCT Publication Date: 2012/03/22
(85) Entrée phase nationale/National Entry: 2013/03/14
(86) N° demande PCT/PCT Application No.: EP 2011/066097
(87) N° publication PCT/PCT Publication No.: 2012/035139
(30) Priorité/Priority: 2010/09/17 (EP10177327.3)

(51) Cl.Int./Int.Cl. *A61K 47/48* (2006.01)
(71) Demandeur/Applicant:
SANOFI-AVENTIS DEUTSCHLAND GMBH, DE
(72) Inventeurs/Inventors:
CLEEMANN, FELIX, DE;
HERSEL, ULRICH, DE;
LESSMANN, TORBEN, DE;
RAU, HARALD, DE
(74) Agent: BERESKIN & PARR LLP/S.E.N.C.R.L.,S.R.L.

(54) Titre : PROMEDICAMENTS COMPRENANT UN CONJUGUE EXENDINE-LIEUR
(54) Title: PRODRUGS COMPRISING AN EXENDIN LINKER CONJUGATE



(57) **Abrégé/Abstract:**

The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an exendin linker conjugate D-L, wherein D represents an exendin moiety; and -L is a non-biologically active linker moiety -L¹ represented by formula (I), wherein the dashed line indicates the attachment to one of the amino groups of the exendin moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by exendin.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
22 March 2012 (22.03.2012)

PCT

(10) International Publication Number
WO 2012/035139 A1(51) International Patent Classification:
A61K 47/48 (2006.01)(21) International Application Number:
PCT/EP2011/066097(22) International Filing Date:
16 September 2011 (16.09.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10177327.3 17 September 2010 (17.09.2010) EP(71) Applicant (for all designated States except US):
SANOFI-AVENTIS DEUTSCHLAND GMBH
[DE/DE]; Brüningstraße 50, 65929 Frankfurt (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CLEEMANN, Felix** [DE/DE]; Turnerstraße 114, 69121 Heidelberg (DE). **HERSEL, Ulrich** [DE/DE]; Fritz-Frey-Straße 8, 69121 Heidelberg (DE). **LESSMANN, Torben** [DE/DE]; Schimperstraße 2, 68167 Mannheim (DE). **RAU, Harald** [DE/DE]; Schwarzwaldstraße 51/2, 69124 Heidelberg (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: PRODRUGS COMPRISING AN EXENDIN LINKER CONJUGATE

(57) Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an exendin linker conjugate D-L, wherein D represents an exendin moiety; and -L is a non-biologically active linker moiety -L¹ represented by formula (I), wherein the dashed line indicates the attachment to one of the amino groups of the exendin moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by exendin.

Prodrugs comprising an exendin linker conjugate

The present invention relates to exendin prodrugs, pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by exendin.

Exendin-4 is a 39-amino acid peptide, isolated from the salivary secretions of the venomous Gila monster (*Heloderma suspectum*). It has some sequence similarity to several members of the glucagon-like peptide family, with the highest homology of 53% being to glucagon-like peptide-1 [7-36]-amide (GLP-1). Exendin-4 acts as a GLP-1 agonist on the GLP-1 receptor and bears GLP-1-like insulin secretagogue action in isolated rat islets. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. (see e.g. J. Biol. Chem. 268(26):19650-19655). Exendin-4 ("exenatide") was approved recently in the US and EU for improving glycemic control in patients with type 2 diabetes taking metformin and/or a sulfonylurea but have not achieved adequate glycemic control.

Current therapy with exenatide requires frequent injections (bidaily), resulting in high plasma levels after injection, which is correlated to nausea (see Nauck M. A., Meier J. J. (2005), *Regul Pept.* 128(2):135-148), and to low trough concentrations, leading to incomplete glycemic control (see Kim D., et al. (2007), *Diabetes Care.* 30(6):1487-1493). To overcome these problems a longer-acting formulation for exendin-4 is highly desirable.

Ideally, the peptide is formulated in a fashion that provides for a sustained plasma level in human for at least one week after application to a human body resulting in a once-weekly or longer injection frequency. Several long-acting exendins have been proposed.

To enhance physicochemical or pharmacokinetic properties of a drug in vivo, such as its half-life, such drug can be conjugated with a carrier. If the drug is transiently bound to a carrier and/or a linker, such systems are commonly assigned as carrier-linked prodrugs. According to the definitions provided by IUPAC (as given under <http://www.chem.qmul.ac.uk/iupac.medchem>, accessed on July 22, 2009), a carrier-

linked prodrug is a prodrug that contains a temporary linkage of a given active substance with a transient carrier group that produces improved physicochemical or pharmacokinetic properties and that can be easily removed *in vivo*, usually by a hydrolytic cleavage.

5

The linkers employed in such carrier-linked prodrugs may be transient, meaning that they are non-enzymatically hydrolytically degradable (cleavable) under physiological conditions (aqueous buffer at pH 7.4, 37°C) with half-lives ranging from, for example, one hour to three months. Suitable carriers are polymers and can either be directly

10

conjugated to the linker or via a non-cleavable spacer.

Transient polymer conjugation through traceless prodrug linkers combines the advantages of prolonged circulation times due to polymer attachment and the recovery of the original pharmacology of the native peptide after release from the polymer

15

conjugate.

Using polymer-linker peptide conjugates, native unchanged peptide is slowly released after application to a patient, governed only by release kinetics of the linker and pharmacokinetics of the polymer carrier. Ideally, release kinetics would be independent

20

from the presence of enzymes like proteases or esterases in body fluids to guarantee a consistent and homogenous release pattern.

The international patent application WO-A 2009/095479 refers to prodrugs comprising drug linker conjugates, where the linker is covalently attached via a cleavable bond to a

25

biologically active moiety, such as exendin. The biologically active moiety is released from the prodrug upon cyclization-activation by cyclic imide formation. An exendin-prodrug is described in which the linker is based on L-alanine.

Still, there remains a need for development of long-acting exendin prodrugs with longer


30

half-lives. Therefore, one object of the present invention is to provide exendin prodrugs with longer half-lives.

This is achieved by a prodrug or a pharmaceutically acceptable salt thereof comprising a covalent exendin prodrug of formula D-L, wherein

D represents an exendin moiety; and

-L is a non-biologically active linker moiety -L¹ represented by formula (I),



wherein the dashed line indicates attachment to one of the amino groups of the exendin by forming an amide bond;

R¹ is selected from C₁₋₄ alkyl, preferably CH₃;

R², R^{2a} are independently selected from the group consisting of H and C₁₋₄ alkyl;

wherein L¹ is substituted with one L²-Z and optionally further substituted, provided that the hydrogens marked with the asterisks in formula (I) are not replaced by a substituent and wherein

L² is a single chemical bond or a spacer; and

Z is a hydrogel.

It was found that prodrug linkers based on the stereochemistry shown in formula (I), i.e. with an amino acid in its D-form, have an advantageous half-life compared to such prodrug linkers based on amino acids in their L-form. Further, such prodrugs may provide exendin release from a subcutaneous depot in structurally intact form over time periods of at least 2 days between administrations. As a further advantage, structural integrity of the released exendin may be provided by a well-hydrated polymer matrix minimizing intermolecular contact of exendin molecules and sustained release may be enabled by means of a self-cleaving prodrug linker between the exendin and the polymer matrix.

Thus it should be possible to administer exendin in form of a prodrug of the present invention less frequently than current long acting exendins. Further advantages should

be a small peak to trough ratio, which greatly reduce the risk of adverse events, such as nausea and gastro intestinal complications. This may help patients to reduce the frequency of injections, while being able to maintain optimal control the plasma levels of exendin and consequently blood glucose.

5

The term “exendin”, refers to an exendin agonist, an exendin analogue, an exendin derivative, a truncated exendin, a truncated exendin agonist, a truncated exendin derivative, a truncated exendin analogue, a extended exendin, a extended exendin agonist, a extended exendin derivative, a extended exendin analogue, GLP-1, a GLP-1 analogue, or a GLP-1 derivative, such as GLP-1 or GLP-1 analogue in amidated, truncated or extended form. Preferably, the exendin is an exendin or an exendin agonist of sequence ID 1 to ID 21 (see below), and more preferred it is exendin-3 having sequence ID 2 or exendin-4 having sequence ID 1.

15 The term “extended” refers to peptides or proteins which have additional amino acid residues at their N-terminal or C-terminal end or which have internal insertions. The term also refers to fusions of said peptides or proteins to other peptides or proteins, such as, for example, GST protein, FLAG peptide, hexa-his peptide, maltose-binding protein.

20

Examples of exendin agonists as used herein are exendin-3 or exendin-4 agonists including but not limited to:

(i) exendin-4 analogues and amidated exendin-4 analogues, in which sequences one or more amino acid residues have been replaced by different amino acid residues including N-terminal modifications;

25

(ii) truncated and extended forms of exendin-4 and truncated and extended forms that are amidated;

30

(iii) truncated and extended exendin-4 and truncated and extended forms that are amidated, in which sequences one or more amino acid residues have been replaced by different amino acid residues;

- (iv) GLP-I and and amidated GLP-I;
- (v) GLP-I-analogues and amidated GLP-I analogues, in which sequences one or more amino acid residues have been replaced by different amin acid residues including N-terminal modifications;
- (vi) truncated and extended GLP-I and truncated and extended forms that are amidated;
- (vii) truncated GLP-I and truncated forms that are amidated, in which sequences one or more amino acid residues have been replaced by different amino acid residues;
- (viii) the already known substances AVE-0010/ZP-10/Lixisenatide (Sanofi-Aventis Zealand Pharma; sequence ID 21), BAY-73-7977 (Bayer), TH-0318, BIM-51077 (Ipsen, Tejin, Roche), NN2211 (Novo Nordisk), LY315902.

Examples of exendin agonists as described above may be those in which an analogue of exendin-4 is selected from a group comprising

H-desPro³⁶-exendin-4-Lys₆-NH₂,

H-des(Pro^{36,37})-exendin-4-Lys₄-NH₂ and

H-des(Pro^{36,37})-exendin-4-Lys₅-NH₂,

or a pharmacologically tolerable salt thereof.

Further examples of exendin agonists as described above may be those in which an analogue of exendin-4 is selected from a group comprising

desPro³⁶ [Asp²⁸]exendin-4 (1-39),

desPro³⁶ [IsoAsp²⁸]exendin-4 (1-39),

desPro³⁶ [Met(O)¹⁴, Asp²⁸]exendin-4 (1-39),

desPro³⁶ [Met(O)¹⁴, IsoAsp²⁸]exendin-4 (1-39),

desPro³⁶ [Trp(O₂)²⁵, Asp²⁸]exendin-2 (1-39),

desPro³⁶ [Trp(O₂)²⁵, IsoAsp²⁸]exendin-2 (1-39),

desPro³⁶ [Met(O)¹⁴Trp(O₂)²⁵, Asp²⁸]exendin-4 (1-39) and

desPro³⁶ [Met(O)¹⁴Trp(O₂)²⁵, IsoAsp²⁸]exendin-4 (1-39),

or a pharmacologically tolerable salt thereof.

- 5 Further examples of exendin agonists as described in the preceding paragraph may be those in which the peptide -Lys₆-NH₂ is attached to the C termini of the analogues of exendin-4.

Further examples of exendin agonists as described above may be those in which an
10 analogue of exendin-4 is selected from a group comprising

H-(Lys)₆- des Pro³⁶ [Asp²⁸]exendin-4(1-39)-Lys₆-NH₂

des Asp²⁸Pro³⁶, Pro³⁷, Pro³⁸ exendin-4(1-39) -NH₂,

H-(Lys)₆- des Pro³⁶, Pro³⁷, Pro³⁸ [Asp²⁸]exendin-4(1-39) -NH₂,

H-Asn-(Glu)₅ des Pro³⁶, Pro³⁷, Pro³⁸ [Asp²⁸]exendin-4(1-39) -NH₂,

15 des Pro³⁶, Pro³⁷, Pro³⁸ [Asp²⁸]exendin-4(1-39)-(Lys)₆-NH₂,

H-(Lys)₆- des Pro³⁶, Pro³⁷, Pro³⁸ [Asp²⁸]exendin-4(1-39)-(Lys)₆-NH₂,

H-Asn-(Glu)₅- des Pro³⁶, Pro³⁷, Pro³⁸ [Asp²⁸]exendin-4(1-39)-(Lys)₆-NH₂,

H-(Lys)₆- des Pro³⁶ [Trp(O₂)²⁵, Asp²⁸]exendin-4(1-39)-Lys₆-NH₂,

20 H- des Asp²⁸ Pro³⁶, Pro³⁷, Pro³⁸ [Trp(O₂)²⁵]exendin-4(1-39) -NH₂,

H-(Lys)₆- des Pro³⁶, Pro³⁷, Pro³⁸ [Trp(O₂)²⁵, Asp²⁸]exendin-4(1-39) -NH₂,

H-Asn-(Glu)₅- des Pro³⁶, Pro³⁷, Pro³⁸ [Trp(O₂)²⁵, Asp²⁸]exendin-4(1-39) -NH₂,

des Pro³⁶, Pro³⁷, Pro³⁸ [Trp(O₂)²⁵, Asp²⁸]exendin-4(1-39)-(Lys)₆-NH₂,

H-(Lys)₆- des Pro³⁶, Pro³⁷, Pro³⁸ [Trp(O₂)²⁵, Asp²⁸]exendin-4(1-39)-(Lys)₆-NH₂,

- H-Asn-(Glu)₅- des Pro³⁶, Pro³⁷, Pro³⁸ [Trp(O₂)²⁵, Asp²⁸]exendin-4(1-39)-(Lys)₆-NH₂,
H-(Lys)₆- des Pro³⁶ [Met(O)¹⁴, Asp²⁸]exendin-4(1-39)-Lys₆-NH₂,
des Met(O)¹⁴ Asp²⁸ Pro³⁶, Pro³⁷, Pro³⁸ exendin-4(1-39) -NH₂,
H-(Lys)₆- des Pro³⁶, Pro³⁷, Pro³⁸ [Met(O)¹⁴, Asp²⁸]exendin-4(1-39) -NH₂,
5 H-Asn-(Glu)₅- des Pro³⁶, Pro³⁷, Pro³⁸ [Met(O)¹⁴, Asp²⁸] exendin-4(1-39) -NH₂,
des Pro³⁶, Pro³⁷, Pro³⁸ [Met(O)¹⁴, Asp²⁸]exendin-4(1-39)-(Lys)₆-NH₂,
H-(Lys)₆- des Pro³⁶, Pro³⁷, Pro³⁸ [Met(O)¹⁴, Asp²⁸]exendin-4(1-39)-Lys₆-NH₂,
H-Asn-(Glu)₅ des Pro³⁶, Pro³⁷, Pro³⁸ [Met(O)¹⁴, Asp²⁸] exendin-4(1-39)-(Lys)₆-NH₂,
10 H-(Lys)₆- des Pro³⁶ [Met(O)¹⁴, Trp(O₂)²⁵, Asp²⁸]exendin-4(1-39)-Lys₆-NH₂,
des Asp²⁸ Pro³⁶, Pro³⁷, Pro³⁸ [Met(O)¹⁴, Trp(O₂)²⁵]exendin-4(1-39) -NH₂,
H-(Lys)₆- des Pro³⁶, Pro³⁷, Pro³⁸ [Met(O)¹⁴, Trp(O₂)²⁵, Asp²⁸]exendin-4(1-39) -NH₂,
H-Asn-(Glu)₅- des Pro³⁶, Pro³⁷, Pro³⁸ [Met(O)¹⁴, Asp²⁸] exendin-4(1-39) -NH₂,
des Pro³⁶, Pro³⁷, Pro³⁸ [Met(O)¹⁴, Trp(O₂)²⁵, Asp²⁸]exendin-4(1-39)-(Lys)₆-NH₂,
15 H-(Lys)₆- des Pro³⁶, Pro³⁷, Pro³⁸ [Met(O)¹⁴, Trp(O₂)²⁵, Asp²⁸]exendin-4(1-39)-(Lys)₆-NH₂,
H-Asn-(Glu)₅- des Pro³⁶, Pro³⁷, Pro³⁸ [Met(O)¹⁴, Trp(O₂)²⁵, Asp²⁸] exendin-4(1-39)-
(Lys)₆-NH₂,

or a pharmacologically tolerable salt thereof.

- A further example of an exendin agonists as described above is Arg³⁴, Lys²⁶ (N^ε(γ-
20 glutamyl(N^α-hexadecanoyl))) GLP-1 (7-37) [liraglutide] or a pharmacologically tolerable
salt thereof.

- Exendin agonists mimic the activities of exendin-3 or exendin-4 by binding the
receptor(s) at which exendin-3 or exendin-4 exerts its actions which are beneficial as
25 insulintropic and in the treatment of diabetes mellitus or by mimicking the effects of
exendin on urine flow, slowing gastric emptying, inducing satiety, increasing urinary

sodium excretion and/or decreasing urinary potassium concentration, by binding to the receptor(s) where exendin cause these effects.

In one embodiment, the exendin or exendin agonists with the Sequence ID NOs: 1-22
5 can be used to prepare the long acting polymeric conjugates of the invention:

[Seq ID No:1] Exendin-4

HGEGTFTSDL SKQMEEEEAVR LFIEWLKNGG PSSGAPPPS-NH2

10 [Seq ID No:2] Exendin-3

HSDGTFTSDL SKQMEEEEAVR LFIEWLKNGG PSSGAPPPS-NH2

[Seq ID No:3]

HGEGTFTSDL SKQMEEEEAVR LFIEWLKNGG P

15

[Seq ID No:4]

HGEGTFTSDL SKQMEEEEAVR LFIEWLKNGG Y

[Seq ID No:5]

20 HGEGTFTSDL SKQMEEEEAVR LFIEWLKNGG

[Seq ID No:6]

HGEGTFTSDL SKQMEEEEAVR LFIEWLKNGG-NH2

25 [Seq ID No:7]

HGEGTFTSDL SKQMEEEEAVR LFIEWLKN-NH2

[Seq ID No:8]

HGEGTFTSDL SKQLEEEAVR LFIEFLKNGG PSSGAPPPS-NH2

30 [Seq ID No:9]

HGEGTFTSDL SKQLEEEAVR LFIEFLKN-NH2

[Seq ID No:10]

HGEGTFTSDL SKQLEEEAVR LAIEFLKN-NH2

[Seq ID No:11]

HGEGTFTSDL SKQLEEEAVR LFIEWLKNNG PSSGAPPPS-NH₂

5 [Seq ID No: 12]

HGDGTFTSDL SKQMEEEA VR LFIEWLKNNG PSSGAPPPS-NH₂

[Seq ID No 13] GLP-I (7-36) amide

HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR-NH₂

10

[Seq ID No 14]

HSEGTFSTSDV SSYLEGQAAK EFIAWLVKGR-NH₂

[Seq ID No 15] GLP-I (7-37)

15 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGRG

[Seq ID No 16]

HAXaaGTFTSDV SSYLEGQAAK EFIAWLVKGR-NH₂

Xaa=P, F, Y

20

[Seq ID No 17]

HXaaEGTFTSDV SSYLEGQAAK EFIAWLVKGR-NH₂

Xaa = T, α-aminobutyric acid, D-Ala, V, Gly

25 [Seq ID No 18]

HaEGTFTSDV SSYLEGQAAK EFIAWLVKGG

[Seq ID No 19]

R-HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR-NH₂

30 R = acetyl, pyroglutamyl, N-2-hydroxybenzoyl, N-trans-3-hexenoyl

[Seq ID No 20]

HXaaAEGTFTSDV SSYLEGQAAK EFIAWLVKGR-NH₂

Xaa = 6-amino-hexanoyl.

[Seq ID No 21] AVE-0010/ZP-10/Lixisenatide

HGEGTFTSDLSKQMEEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH₂

[Seq ID No 22] Arg³⁴, Lys²⁶ (N^ε(γ-glutamyl(N^α-hexadecanoyl))) GLP-1 (7-37) [liraglutide]

5 HAEGTFTSDV SSYLEGQAAXaaEFIAWLVRGRG

Xaa = Lys(N^ε(γ-glutamyl(N^α-hexadecanoyl)))

Preferably, the exendin is having the sequence ID 1, ID 13, ID 15, ID 21 or ID 22.

More preferably, the exendin is having the sequence ID 1, ID 13 or ID 21.

10

In one embodiment, the exendin is exendin-4 having sequence ID 1.

In another embodiment, the exendin is an analog having sequence ID 13.

In another embodiment, the exendin is an analog having sequence ID 21.

15 The exendin and exendin agonists derivatives of the invention will exert any and all activities exhibited by the parent non-modified molecule, but with a prolonged action.

Exendin bound to a non-biologically active linker is referred to as "exendin moiety".

20 "Non-biologically active linker" means a linker which does not show the pharmacological effects of the drug derived from the biologically active agent.

"Protective groups" refers to a moiety which temporarily protects a chemical functional group of a molecule during synthesis to obtain chemoselectivity in subsequent chemical reactions. Protective groups for alcohols are, for example, benzyl and trityl, protective groups for amines are, for example, tert-butyloxycarbonyl, 9-fluorenylmethyloxycarbonyl and benzyl and for thiols examples of protective groups are 2,4,6-trimethoxybenzyl, phenylthiomethyl, acetamidomethyl, p-methoxybenzyloxycarbonyl, tert-butylthio, triphenylmethyl, 3-nitro-2-pyridylthio, 4-methyltrityl.

30

"Protected functional groups" means a chemical functional group protected by a protective group.

"Acylating agent" means a moiety of the structure $R-(C=O)-$, providing the acyl group in an acylation reaction, optionally connected to a leaving group, such as acid chloride, N-hydroxy succinimide, pentafluorophenol and para-nitrophenol.

5 "Alkyl" means a straight-chain or branched carbon chain. Each hydrogen of an alkyl carbon may be replaced by a substituent.

"Aryl" refers to any substituent derived from a monocyclic or polycyclic or fused aromatic ring, including heterocyclic rings, e.g. phenyl, thiophene, indolyl, naphthyl, pyridyl, which
10 may optionally be further substituted.

"Acyl" means a chemical functional group of the structure $R-(C=O)-$, wherein R is an alkyl or aryl.

15 "C₁₋₄ alkyl" means an alkyl chain having 1 - 4 carbon atoms, e.g. if present at the end of a molecule: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, or e.g. $-CH_2-$, $-CH_2-CH_2-$, $-CH(CH_3)-$, $-CH_2-CH_2-CH_2-$, $-CH(C_2H_5)-$, $-C(CH_3)_2-$, when two moieties of a molecule are linked by the alkyl group. Each hydrogen of a C₁₋₄ alkyl carbon may be replaced by a substituent.

20 "C₁₋₆ alkyl" means an alkyl chain having 1 - 6 carbon atoms, e.g. if present at the end of a molecule: C₁₋₄ alkyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, or e.g. $-CH_2-$, $-CH_2-CH_2-$, $-CH(CH_3)-$, $-CH_2-CH_2-CH_2-$, $-CH(C_2H_5)-$, $-C(CH_3)_2-$, when two moieties of a molecule are linked by the alkyl group.
25 Each hydrogen of a C₁₋₆ alkyl carbon may be replaced by a substituent.

Accordingly, "C₁₋₁₈ alkyl" means an alkyl chain having 1 to 18 carbon atoms and "C₈₋₁₈ alkyl" means an alkyl chain having 8 to 18 carbon atoms. Accordingly, "C₁₋₅₀ alkyl" means an alkyl chain having 1 to 50 carbon atoms.

30 "C₂₋₅₀ alkenyl" means a branched or unbranched alkenyl chain having 2 to 50 carbon atoms, e.g. if present at the end of a molecule: $-CH=CH_2$, $-CH=CH-CH_3$, $-CH_2-CH=CH_2$, $-CH=CH-CH_2-CH_3$, $-CH=CH-CH=CH_2$, or e.g. $-CH=CH-$, when two moieties of a molecule are linked by the alkenyl group. Each hydrogen of a C₂₋₅₀ alkenyl carbon may

be replaced by a substituent as further specified. Accordingly, the term "alkenyl" relates to a carbon chain with at least one carbon-carbon double bond. Optionally, one or more triple bonds may occur.

5 "C₂₋₅₀ alkynyl" means a branched or unbranched alkynyl chain having 2 to 50 carbon atoms, e.g. if present at the end of a molecule: -C≡CH, -CH₂-C≡CH, CH₂-CH₂-C≡CH, CH₂-C≡C-CH₃, or e.g. -C≡C- when two moieties of a molecule are linked by the alkynyl group. Each hydrogen of a C₂₋₅₀ alkynyl carbon may be replaced by a substituent as further specified. Accordingly, the term "alkynyl" relates to a carbon chain with at least
10 one carbon-carbon triple bond. Optionally, one or more double bonds may occur.

"C₃₋₇ cycloalkyl" or "C₃₋₇ cycloalkyl ring" means a cyclic alkyl chain having 3 to 7 carbon atoms, which may have carbon-carbon double bonds being at least partially saturated, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl. Each
15 hydrogen of a cycloalkyl carbon may be replaced by a substituent. The term "C₃₋₇ cycloalkyl" or "C₃₋₇ cycloalkyl ring" also includes bridged bicycles like norbornane or norbornene. Accordingly, "C₃₋₅ cycloalkyl" means a cycloalkyl having 3 to 5 carbon atoms.

20 Accordingly, "C₃₋₁₀ cycloalkyl" means a cyclic alkyl having 3 to 10 carbon atoms, e.g. C₃₋₇ cycloalkyl; cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl. The term "C₃₋₁₀ cycloalkyl" also includes at least partially saturated carbomono- and -bicycles.

25 "Halogen" means fluoro, chloro, bromo or iodo. It is generally preferred that halogen is fluoro or chloro.

"4 to 7 membered heterocyclyl" or "4 to 7 membered heterocycle" means a ring with 4, 5, 6 or 7 ring atoms that may contain up to the maximum number of double bonds
30 (aromatic or non-aromatic ring which is fully, partially or un-saturated) wherein at least one ring atom up to 4 ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including -S(O)-, -S(O)₂-), oxygen and nitrogen (including =N(O)-) and wherein the ring is linked to the rest of the molecule via a carbon or nitrogen atom. Examples for a 4 to 7 membered heterocycles are azetidine, oxetane, thietane, furan,

thiophene, pyrrole, pyrroline, imidazole, imidazoline, pyrazole, pyrazoline, oxazole, oxazoline, isoxazole, isoxazoline, thiazole, thiazoline, isothiazole, isothiazoline, thiadiazole, thiadiazoline, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, sulfolane, pyran, dihydropyran, tetrahydropyran, imidazolidine, pyridine, pyridazine, pyrazine, pyrimidine, piperazine, piperidine, morpholine, tetrazole, triazole, triazolidine, tetrazolidine, diazepane, azepine or homopiperazine.

"9 to 11 membered heterobicycyl" or "9 to 11 membered heterobicycle" means a

heterocyclic system of two rings with 9 to 11 ring atoms, where at least one ring atom is shared by both rings and that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or un-saturated) wherein at least one ring atom up to 6 ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including -S(O)-, -S(O)₂-), oxygen and nitrogen (including =N(O)-) and wherein the ring is linked to the rest of the molecule via a carbon or nitrogen atom. Examples for a 9 to 11 membered heterobicycle are indole, indoline, benzofuran, benzothiophene, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole, benzimidazole, benzimidazoline, quinoline, quinazoline, dihydroquinazoline, quinoline, dihydroquinoline, tetrahydroquinoline, decahydroquinoline, isoquinoline, decahydroisoquinoline, tetrahydroisoquinoline, dihydroisoquinoline, benzazepine, purine or pteridine. The term 9 to 11 membered heterobicycle also includes spiro structures of two rings like 1,4-dioxo-8-azaspiro[4.5]decane or bridged heterocycles like 8-aza-bicyclo[3.2.1]octane.

In case the exendin prodrugs comprising the compounds according to formula (I) contain one or more acidic or basic groups, the invention also comprises their corresponding pharmaceutically or toxicologically acceptable salts, in particular their pharmaceutically utilizable salts. Thus, the exendin prodrugs comprising the compounds of the formula (I) which contain acidic groups can be used according to the invention, for example, as alkali metal salts, alkaline earth metal salts or as ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids. Exendin prodrugs comprising the compounds of the formula (I) which contain one or more basic groups,

i.e. groups which can be protonated, can be present and can be used according to the invention in the form of their addition salts with inorganic or organic acids. Examples for suitable acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to the person skilled in the art. If the exendin prodrugs comprising the compounds of the formula (I) simultaneously contain acidic and basic groups in the molecule, the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions). The respective salts according to exendin prodrugs comprising the formula (I) can be obtained by customary methods which are known to the person skilled in the art like, for example by contacting these with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts. The present invention also includes all salts of the exendin prodrugs comprising the compounds of the formula (I) which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.

To enhance physicochemical or pharmacokinetic properties of a drug, such as exendin, *in vivo*, such drug can be conjugated with a carrier. If the drug is transiently bound to a carrier and/or a linker, such systems are commonly assigned as carrier-linked prodrugs. According to the definitions provided by IUPAC (as given under <http://www.chem.qmul.ac.uk/iupac.medchem>, accessed on July 22, 2009), a carrier-linked prodrug is a prodrug that contains a temporary linkage of a given active substance with a transient carrier group that produces improved physicochemical or pharmacokinetic properties and that can be easily removed *in vivo*, usually by a hydrolytic cleavage.

The linkers employed in such carrier-linked prodrugs are transient, meaning that they are non-enzymatically hydrolytically degradable (cleavable) under physiological

conditions (aqueous buffer at pH 7.4, 37°C) with half-lives ranging from, for example, one hour to three months.

The hydrogel carriers can either be directly conjugated to the linker L or via a spacer, preferably a non-cleavable spacer. The term "exendin hydrogel prodrug" refers to carrier-linked prodrugs of exendin, wherein the carrier is a hydrogel. The terms "hydrogel prodrug" and "hydrogel-linked prodrug" refer to prodrugs of biologically active agents transiently linked to a hydrogel and are used synonymously.

A "hydrogel" may be defined as a three-dimensional, hydrophilic or amphiphilic polymeric network capable of taking up large quantities of water. The networks are composed of homopolymers or copolymers, are insoluble due to the presence of covalent chemical or physical (ionic, hydrophobic interactions, entanglements) crosslinks. The crosslinks provide the network structure and physical integrity.

Hydrogels exhibit a thermodynamic compatibility with water which allows them to swell in aqueous media. The chains of the network are connected in such a fashion that pores exist and that a substantial fraction of these pores are of dimensions between 1 nm and 1000 nm.

"Free form" of a drug refers to a drug, specifically to exendin, in its unmodified, pharmacologically active form, such as after being released from a polymer conjugate.

It is understood that the pharmacologically active form of exendin also includes oxidized and deamidated drug.

The terms "drug", "biologically active molecule", "biologically active moiety", "biologically active agent", "active agent", are used synonymously and refer to exendin, either in its bound or free form.

A "therapeutically effective amount" of exendin as used herein means an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of a given disease and its complications. An amount adequate to accomplish this is defined as "therapeutically effective amount". Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the

subject. It will be understood that determining an appropriate dosage may be achieved using routine experimentation, by constructing a matrix of values and testing different points in the matrix, which is all within the ordinary skills of a trained physician.

5 “Stable” and “stability” means that within the indicated storage time the hydrogel conjugates remain conjugated and do not hydrolyze to a substantial extent and exhibit an acceptable impurity profile relating to exendin. To be considered stable, the composition contains less than 5% of the drug in its free form.

10 The term “pharmaceutically acceptable” means approved by a regulatory agency such as the EMEA (Europe) and/or the FDA (US) and/or any other national regulatory agency for use in animals, preferably in humans.

“Pharmaceutical composition” or “composition” means one or more active ingredients,
15 and one or more inert ingredients, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition
20 made by admixing a compound of the present invention and a pharmaceutically acceptable excipient (pharmaceutically acceptable carrier).

“Dry composition” means that the exendin hydrogel prodrug composition is provided in a dry form in a container. Suitable methods for drying are spray-drying and lyophilization
25 (freeze-drying). Such dry composition of exendin hydrogel prodrug has a residual water content of a maximum of 10 %, preferably less than 5% and more preferably less than 2% (determined according to Karl Fischer). The preferred method of drying is lyophilization. “Lyophilized composition” means that the exendin hydrogel polymer prodrug composition was first frozen and subsequently subjected to water reduction by
30 means of reduced pressure. This terminology does not exclude additional drying steps which occur in the manufacturing process prior to filling the composition into the final container.

“Lyophilization” (freeze-drying) is a dehydration process, characterized by freezing a composition and then reducing the surrounding pressure and, optionally, adding heat to allow the frozen water in the composition to sublime directly from the solid phase to gas. Typically, the sublimed water is collected by desublimation.

5

“Reconstitution” means the addition of a liquid to a dry composition to bring it into the form of a liquid or suspension composition. It is understood that the term “reconstitution” is not limited to the addition of water, but refers to the addition of any liquid, including for example buffers or other aqueous solutions.

10

“Reconstitution solution” refers to the liquid used to reconstitute the dry composition of an exendin hydrogel prodrug prior to administration to a patient in need thereof.

“Container” means any container in which the exendin hydrogel prodrug composition is comprised and can be stored until reconstitution.

15

“Buffer” or “buffering agent” refers to chemical compounds that maintain the pH in a desired range. Physiologically tolerated buffers are, for example, sodium phosphate, succinate, histidine, bicarbonate, citrate and acetate, pyruvate. Antacids such as Mg(OH)₂ or ZnCO₃ may be also used. Buffering capacity may be adjusted to match the conditions most sensitive to pH stability.

20

“Excipients” refers to compounds administered together with the therapeutic agent, for example, buffering agents, isotonicity modifiers, preservatives, stabilizers, anti-adsorption agents, oxidation protection agents, or other auxiliary agents. However, in some cases, one excipient may have dual or triple functions.

25

A “lyoprotectant” is a molecule which, when combined with a protein of interest, significantly prevents or reduces chemical and/or physical instability of the protein upon drying in general and especially during lyophilization and subsequent storage.

30

Exemplary lyoprotectants include sugars, such as sucrose or trehalose; amino acids such as arginine, glycine, glutamate or histidine; methylamines such as betaine; lyotropic salts such as magnesium sulfate; polyols such as trihydric or higher sugar alcohols, e.g. glycerin, erythritol, glycerol, arabitol, xylitol, sorbitol, and mannitol;

ethylene glycol; propylene glycol; polyethylene glycol; pluronics; hydroxyalkyl starches, e.g. hydroxyethyl starch (HES), and combinations thereof.

“Surfactant” refers to wetting agents that lower the surface tension of a liquid.

5

“Isotonicity modifiers” refer to compounds which minimize pain that can result from cell damage due to osmotic pressure differences at the injection depot.

The term “stabilizers” refers to compounds used to stabilize the polymer prodrug.

10 Stabilisation is achieved by strengthening of the protein-stabilising forces, by destabilisation of the denatured state, or by direct binding of excipients to the protein.

“Anti-adsorption agents” refers to mainly ionic or non-ionic surfactants or other proteins or soluble polymers used to coat or adsorb competitively to the inner surface of the composition’s container. Chosen concentration and type of excipient depends on the effect to be avoided but typically a monolayer of surfactant is formed at the interface just above the CMC value.

15

“Oxidation protection agents” refers to antioxidants such as ascorbic acid, ectoine, glutathione, methionine, monothioglycerol, morin, polyethylenimine (PEI), propyl gallate, vitamin E, chelating agents such as citric acid, EDTA, hexaphosphate, thioglycolic acid.

20

“Antimicrobial” refers to a chemical substance that kills or inhibits the growth of microorganisms, such as bacteria, fungi, yeasts, protozoans and/or destroys viruses.

25

“Sealing a container” means that the container is closed in such way that it is airtight, allowing no gas exchange between the outside and the inside and keeping the content sterile.

30

The term “reagent” or “precursor” refers to an intermediate or starting material used in the assembly process leading to a prodrug of the present invention.

The term “chemical functional group” refers to carboxylic acid and activated derivatives, amino, maleimide, thiol and derivatives, sulfonic acid and derivatives, carbonate and derivatives, carbamate and derivatives, hydroxyl, aldehyde, ketone, hydrazine, isocyanate, isothiocyanate, phosphoric acid and derivatives, phosphonic acid and derivatives, haloacetyl, alkyl halides, acryloyl and other alpha-beta unsaturated michael acceptors, arylating agents like aryl fluorides, hydroxylamine, disulfides like pyridyl disulfide, vinyl sulfone, vinyl ketone, diazoalkanes, diazoacetyl compounds, oxirane, and aziridine.

If a chemical functional group is coupled to another chemical functional group, the resulting chemical structure is referred to as “linkage”. For example, the reaction of an amine group with a carboxyl group results in an amide linkage.

“Reactive functional groups” are chemical functional groups of the backbone moiety, which are connected to the hyperbranched moiety.

“Functional group” is the collective term used for “reactive functional group”, “degradable interconnected functional group”, or “conjugate functional group”.

A “degradable interconnected functional group” is a linkage comprising a biodegradable bond which on one side is connected to a spacer moiety connected to a backbone moiety and on the other side is connected to the crosslinking moiety. The terms “degradable interconnected functional group”, “biodegradable interconnected functional group”, “interconnected biodegradable functional group” and “interconnected functional group” are used synonymously.

The terms “blocking group” or “capping group” are used synonymously and refer to moieties which are irreversibly connected to reactive functional groups to render them incapable of reacting with for example chemical functional groups.

The terms “protecting group” or “protective group” refers to a moiety which is reversibly connected to reactive functional groups to render them incapable of reacting with for example other chemical functional groups.

The term “interconnectable functional group” refers to chemical functional groups, which participate in a radical polymerization reaction and are part of the crosslinker reagent or the backbone reagent.

- 5 The term “polymerizable functional group” refers to chemical functional groups, which participate in a ligation-type polymerization reaction and are part of the crosslinker reagent and the backbone reagent.

10 A backbone moiety may comprise a spacer moiety which at one end is connected to the backbone moiety and on the other side to the crosslinking moiety.

The term “derivatives” refers to chemical functional groups suitably substituted with protecting and/or activation groups or to activated forms of a corresponding chemical functional group which are known to the person skilled in the art. For example, activated
15 forms of carboxyl groups include but are not limited to active esters, such as succinimidyl ester, benzotriazyl ester, nitrophenyl ester, pentafluorophenyl ester, azabenzotriazyl ester, acyl halogenides, mixed or symmetrical anhydrides, acyl imidazole.

- 20 The term “non-enzymatically cleavable linker” refers to linkers that are hydrolytically degradable under physiological conditions without enzymatic activity.

“Non-biologically active linker” means a linker which does not show the pharmacological effects of the drug (D-H) derived from the biologically active moiety.

25 The terms “spacer”, “spacer group”, “spacer molecule”, and “spacer moiety” are used interchangeably and if used to describe a moiety present in the hydrogel carrier of the invention, refer to any moiety suitable for connecting two moieties, such as C₁₋₅₀ alkyl, C₂₋₅₀ alkenyl or C₂₋₅₀ alkynyl, which fragment is optionally interrupted by one or more
30 groups selected from -NH-, -N(C₁₋₄ alkyl)-, -O-, -S-, -C(O)-, -C(O)NH-, -C(O)N(C₁₋₄ alkyl)-, -O-C(O)-, -S(O)-, -S(O)₂-, 4 to 7 membered heterocyclyl, phenyl or naphthyl.

The terms “terminal”, “terminus” or “distal end” refer to the position of a functional group or linkage within a molecule or moiety, whereby such functional group may be a

chemical functional group and the linkage may be a degradable or permanent linkage, characterized by being located adjacent to or within a linkage between two moieties or at the end of an oligomeric or polymeric chain.

- 5 The phrases “in bound form” or “moiety” refer to sub-structures which are part of a larger molecule. The phrase “in bound form” is used to simplify reference to moieties by naming or listing reagents, starting materials or hypothetical starting materials well known in the art, and whereby “in bound form” means that for example one or more hydrogen radicals ($-H$), or one or more activating or protecting groups present in the
10 reagents or starting materials are not present in the moiety.

It is understood that all reagents and moieties comprising polymeric moieties refer to macromolecular entities known to exhibit variabilities with respect to molecular weight, chain lengths or degree of polymerization, or the number of functional groups.

- 15 Structures shown for backbone reagents, backbone moieties, crosslinker reagents, and crosslinker moieties are thus only representative examples.

- A reagent or moiety may be linear or branched. If the reagent or moiety has two terminal groups, it is referred to as a linear reagent or moiety. If the reagent or moiety
20 has more than two terminal groups, it is considered to be a branched or multi-functional reagent or moiety.

The term “poly(ethylene glycol) based polymeric chain” or “PEG based chain” refers to an oligo- or polymeric molecular chain.

- 25 Preferably, such poly(ethylene glycol) based polymeric chain is connected to a branching core, it is a linear poly(ethylene glycol) chain, of which one terminus is connected to the branching core and the other to a hyperbranched dendritic moiety. It is understood that a PEG-based chain may be terminated or interrupted by alkyl or aryl
30 groups optionally substituted with heteroatoms and chemical functional groups.


If the term “poly(ethylene glycol) based polymeric chain” is used in reference to a crosslinker reagent, it refers to a crosslinker moiety or chain comprising at least 20 weight % ethylene glycol moieties.

In the following sections the invention is described in further detail.

The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof, comprising an exendin linker conjugate D-L, wherein

5 D represents an exendin moiety; and

-L is a non-biologically active linker moiety -L¹ represented by formula (I),



10

wherein the dashed line indicates the attachment to one of the amino groups of the exendin moiety by forming an amide bond;

R¹ is selected from C₁₋₄ alkyl, preferably CH₃;

15

R², R^{2a} are independently selected from the group consisting of H and C₁₋₄ alkyl; wherein L¹ is substituted with one L²-Z and optionally further substituted, provided that the hydrogens marked with the asterisks in formula (I) are not replaced by a substituent and wherein

20

L² is a single chemical bond or a spacer; and

Z is a hydrogel.

25 Preferably, in formula (I) R² is replaced by L²-Z.


Preferably, in formula (I) R¹ is CH₂-L²-Z.

Preferably, L¹ is not further substituted.


30

Preferably, the exendin moiety is attached to L^1 through the N-terminal nitrogen or through a nitrogen of a lysine side chain of the exendin moiety. Most preferably, the exendin moiety is attached to L^1 through the N-terminal nitrogen.

- 5 Preferred prodrugs of the present invention comprise exendin linker conjugates D-L, wherein L is represented by formulae (Ia) or (Ib):



10



- wherein D, R^1 , R^2 , R^{2a} , L^2 , Z have the meaning and preferred meaning as indicated herein and wherein L is optionally further substituted, provided that the hydrogens marked with the asterisks in formula (Ia) or (Ib) are not replaced by a substituent, however preferably L is not further substituted (apart from the mandatory substituent L^2 -Z already shown in (Ia) and (Ib)).
- 15

- As shown in, e.g., formulae (Ia) or (Ib), one hydrogen of L^1 of formula (I) is replaced by the group L^2 -Z.
- 20

- In general, L^2 can be attached to L^1 in formula (I) at any position apart from the replacement of the hydrogens marked with the asterisks. Preferably, one of the hydrogens given by R^1 , R^2 , R^{2a} , directly or as hydrogen of the C_{1-4} alkyl or further groups is replaced by L^2 -Z.
- 25

Furthermore, L^1 of formula (I) may be optionally further substituted. In general, any substituent may be used as far as the cleavage is not affected. However it is preferred that L^1 is not further substituted.

- 5 Preferably, one or more further optional substituents are independently selected from the group consisting of halogen; CN; COOR⁹; OR⁹; C(O)R⁹; C(O)N(R⁹R^{9a}); S(O)₂N(R⁹R^{9a}); S(O)N(R⁹R^{9a}); S(O)₂R⁹; S(O)R⁹; N(R⁹)S(O)₂N(R^{9a}R^{9b}); SR⁹; N(R⁹R^{9a}); NO₂; OC(O)R⁹; N(R⁹)C(O)R^{9a}; N(R⁹)S(O)₂R^{9a}; N(R⁹)S(O)R^{9a}; N(R⁹)C(O)OR^{9a}; N(R⁹)C(O)N(R^{9a}R^{9b}); OC(O)N(R⁹R^{9a}); T; C₁₋₅₀ alkyl; C₂₋₅₀ alkenyl; or C₂₋₅₀ alkynyl,
 10 wherein T; C₁₋₅₀ alkyl; C₂₋₅₀ alkenyl; and C₂₋₅₀ alkynyl are optionally substituted with one or more R¹⁰, which are the same or different and wherein C₁₋₅₀ alkyl; C₂₋₅₀ alkenyl; and C₂₋₅₀ alkynyl are optionally interrupted by one or more groups selected from the group consisting of T, -C(O)O-; -O-; -C(O)-; -C(O)N(R¹¹)-; -S(O)₂N(R¹¹)-; -S(O)N(R¹¹)-; -S(O)₂-; -S(O)-; -N(R¹¹)S(O)₂N(R^{11a})-; -S-; -N(R¹¹)-; -OC(O)R¹¹; -N(R¹¹)C(O)-; -N(R¹¹)S(O)₂-; -
 15 N(R¹¹)S(O)-; -N(R¹¹)C(O)O-; -N(R¹¹)C(O)N(R^{11a})-; and -OC(O)N(R¹¹R^{11a});

- R⁹, R^{9a}, R^{9b} are independently selected from the group consisting of H; T; and C₁₋₅₀ alkyl; C₂₋₅₀ alkenyl; or C₂₋₅₀ alkynyl, wherein T; C₁₋₅₀ alkyl; C₂₋₅₀ alkenyl; and C₂₋₅₀ alkynyl are optionally substituted with one or more R¹⁰, which are the same or different and
 20 wherein C₁₋₅₀ alkyl; C₂₋₅₀ alkenyl; and C₂₋₅₀ alkynyl are optionally interrupted by one or more groups selected from the group consisting of T, -C(O)O-; -O-; -C(O)-; -C(O)N(R¹¹)-; -S(O)₂N(R¹¹)-; -S(O)N(R¹¹)-; -S(O)₂-; -S(O)-; -N(R¹¹)S(O)₂N(R^{11a})-; -S-; -N(R¹¹)-; -OC(O)R¹¹; -N(R¹¹)C(O)-; -N(R¹¹)S(O)₂-; -N(R¹¹)S(O)-; -N(R¹¹)C(O)O-; -N(R¹¹)C(O)N(R^{11a})-; and -OC(O)N(R¹¹R^{11a});

- 25 T is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl; tetralinyl; C₃₋₁₀ cycloalkyl; 4 to 7 membered heterocyclyl; or 9 to 11 membered heterobicyclyl, wherein T is optionally substituted with one or more R¹⁰, which are the same or different;

- 30 R¹⁰ is halogen; CN; oxo (=O); COOR¹²; OR¹²; C(O)R¹²; C(O)N(R¹²R^{12a}); S(O)₂N(R¹²R^{12a}); S(O)N(R¹²R^{12a}); S(O)₂R¹²; S(O)R¹²; N(R¹²)S(O)₂N(R^{12a}R^{12b}); SR¹²; N(R¹²R^{12a}); NO₂; OC(O)R¹²; N(R¹²)C(O)R^{12a}; N(R¹²)S(O)₂R^{12a}; N(R¹²)S(O)R^{12a};

$N(R^{12})C(O)OR^{12a}$; $N(R^{12})C(O)N(R^{12a}R^{12b})$; $OC(O)N(R^{12}R^{12a})$; or C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted with one or more halogen, which are the same or different;

R^{11} , R^{11a} , R^{12} , R^{12a} , R^{12b} are independently selected from the group consisting of H; or
 5 C_{1-6} alkyl, wherein C_{1-6} alkyl is optionally substituted with one or more halogen, which are the same or different.

The term "interrupted" means that between two carbons a group is inserted or at the end of the carbon chain between the carbon and hydrogen.

10 L^2 is a single chemical bond or a spacer. In case L^2 is a spacer, it is preferably defined as the one or more optional substituents defined above, provided that L^2 is substituted with Z.

Accordingly, when L^2 is other than a single chemical bond, L^2-Z is $COOR^9$; OR^9 ;
 15 $C(O)R^9$; $C(O)N(R^9R^{9a})$; $S(O)_2N(R^9R^{9a})$; $S(O)N(R^9R^{9a})$; $S(O)_2R^9$; $S(O)R^9$;
 $N(R^9)S(O)_2N(R^{9a}R^{9b})$; SR^9 ; $N(R^9R^{9a})$; $OC(O)R^9$; $N(R^9)C(O)R^{9a}$; $N(R^9)S(O)_2R^{9a}$;
 $N(R^9)S(O)R^{9a}$; $N(R^9)C(O)OR^{9a}$; $N(R^9)C(O)N(R^{9a}R^{9b})$; $OC(O)N(R^9R^{9a})$; T; C_{1-50} alkyl; C_{2-50} alkenyl; or C_{2-50} alkynyl, wherein T; C_{1-50} alkyl; C_{2-50} alkenyl; and C_{2-50} alkynyl are optionally substituted with one or more R^{10} , which are the same or different and wherein
 20 C_{1-50} alkyl; C_{2-50} alkenyl; and C_{2-50} alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-; -O-; -C(O)-; -C(O)N(R^{11})-; -
 $S(O)_2N(R^{11})$ -; -S(O)N(R^{11})-; -S(O)₂-; -S(O)-; -N(R^{11})S(O)₂N(R^{11a})-; -S-; -N(R^{11})-; -
 $OC(O)R^{11}$; -N(R^{11})C(O)-; -N(R^{11})S(O)₂-; -N(R^{11})S(O)-; -N(R^{11})C(O)O-; -
 $N(R^{11})C(O)N(R^{11a})$ -; and -OC(O)N($R^{11}R^{11a}$);

25 R^9 , R^{9a} , R^{9b} are independently selected from the group consisting of H; Z; T; and C_{1-50} alkyl; C_{2-50} alkenyl; or C_{2-50} alkynyl, wherein T; C_{1-50} alkyl; C_{2-50} alkenyl; and C_{2-50} alkynyl are optionally substituted with one or more R^{10} , which are the same or different and wherein C_{1-50} alkyl; C_{2-50} alkenyl; and C_{2-50} alkynyl are optionally interrupted by one or
 30 more groups selected from the group consisting of T, -C(O)O-; -O-; -C(O)-; -C(O)N(R^{11})-; -
 $S(O)_2N(R^{11})$ -; -S(O)N(R^{11})-; -S(O)₂-; -S(O)-; -N(R^{11})S(O)₂N(R^{11a})-; -S-; -N(R^{11})-; -
 $OC(O)R^{11}$; -N(R^{11})C(O)-; -N(R^{11})S(O)₂-; -N(R^{11})S(O)-; -N(R^{11})C(O)O-; -
 $N(R^{11})C(O)N(R^{11a})$ -; and -OC(O)N($R^{11}R^{11a}$);

T is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl; tetralinyl; C₃₋₁₀ cycloalkyl; 4 to 7 membered heterocyclyl; or 9 to 11 membered heterobicyclyl, wherein t is optionally substituted with one or more R¹⁰, which are the same or different;

- 5 R¹⁰ is Z; halogen; CN; oxo (=O); COOR¹²; OR¹²; C(O)R¹²; C(O)N(R¹²R^{12a}); S(O)₂N(R¹²R^{12a}); S(O)N(R¹²R^{12a}); S(O)₂R¹²; S(O)R¹²; N(R¹²)S(O)₂N(R^{12a}R^{12b}); SR¹²; N(R¹²R^{12a}); NO₂; OC(O)R¹²; N(R¹²)C(O)R^{12a}; N(R¹²)S(O)₂R^{12a}; N(R¹²)S(O)R^{12a}; N(R¹²)C(O)OR^{12a}; N(R¹²)C(O)N(R^{12a}R^{12b}); OC(O)N(R¹²R^{12a}); or C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with one or more halogen, which are the same or different;


10 R¹¹, R^{11a}, R¹², R^{12a}, R^{12b} are independently selected from the group consisting of H; Z; or C₁₋₆ alkyl, wherein C₁₋₆ alkyl is optionally substituted with one or more halogen, which are the same or different;

- 15 provided that only one of R⁹, R^{9a}, R^{9b}, R¹⁰, R¹¹, R^{11a}, R¹², R^{12a}, R^{12b} is Z.

More preferably, L² is a C₁₋₂₀ alkyl chain, which is optionally interrupted by one or more groups independently selected from -O-; and C(O)N(R^{3aa}); optionally substituted with one or more groups independently selected from OH; and C(O)N(R^{3aa}R^{3aaa}); and wherein R^{3aa}, R^{3aaa} are independently selected from the group consisting of H; and C₁₋₄ alkyl.

Preferably, L² has a molecular weight in the range of from 14 g/mol to 750 g/mol.

Preferably, L² is attached to Z via a terminal group selected from



In case L² has such terminal group it is furthermore preferred that L² has a molecular weight in the range of from 14 g/mol to 500 g/mol calculated without such terminal group.

Preferably, the covalent attachment formed between the linker and Z is a permanent bond.

Preferably, the hydrogel Z is a biodegradable poly(ethylene glycol) (PEG) based water-insoluble hydrogel. The term "PEG based" as understood herein means that the mass proportion of PEG chains in the hydrogel is at least 10% by weight, preferably at least 25%, based on the total weight of the hydrogel. The remainder can be made up of other spacers and/or oligomers or polymers, such as oligo- or polylysines.

Moreover the term "water-insoluble" refers to a swellable three-dimensionally crosslinked molecular network forming the hydrogel. The hydrogel if suspended in a large surplus of water or aqueous buffer of physiological osmolality may take up a substantial amount of water, e.g. up to 10-fold on a weight per weight basis, and is therefore swellable but after removing excess water still retains the physical stability of a gel and a shape. Such shape may be of any geometry and it is understood that such an individual hydrogel object is to be considered as a single molecule consisting of components wherein each component is connected to each other component through chemical bonds.

According to this invention, the hydrogel may be composed of backbone moieties interconnected by hydrolytically degradable bonds. Preferably, the hydrogel is a PEG-based hydrogel comprised of backbone moieties.

Preferably, L^2 is connected to a backbone moiety.

Preferably, the backbone moiety has a molecular weight in the range of from 1 kDa to 20 kDa, more preferably from 1 kDa to 15 kDa and even more preferably from 1 kDa to 10 kDa. The backbone moieties are preferably also PEG-based comprising one or more PEG chains.

In a hydrogel carrying exendin-linker conjugates according to the invention, a backbone moiety is characterized by a number of functional groups, comprising interconnected biodegradable functional groups and hydrogel-connected drug-linker conjugates, and optionally capping groups. This means that a backbone moiety is characterized by a

number of hydrogel-connected drug-linker conjugates; functional groups, comprising biodegradable interconnected functional groups; and optionally capping groups.

Preferably, the sum of interconnected biodegradable functional groups and drug-linker conjugates and capping groups is 16-128, preferred 20-100, more preferred 24-80 and most preferred 30-60.

Preferably, the sum of interconnected functional groups and hydrogel-connected drug-linker conjugates and capping groups of a backbone moiety is equally divided by the number of PEG-based polymeric chains extending from the branching core. For instance, if there are 32 interconnected functional groups and hydrogel-connected drug-linker conjugates and capping groups, eight groups may be provided by each of the four PEG-based polymeric chains extending from the core, preferably by means of dendritic moieties attached to the terminus of each PEG-based polymeric chain. Alternatively, four groups may be provided by each of eight PEG-based polymeric chains extending from the core or two groups by each of sixteen PEG-based polymeric chains. If the number of PEG-based polymeric chains extending from the branching core does not allow for an equal distribution, it is preferred that the deviation from the mean number of the sum of interconnected functional groups and hydrogel-connected drug-linker conjugates and capping groups per PEG-based polymeric chain is kept to a minimum.

In such carrier-linked prodrugs according to the invention, it is desirable that almost all drug release (> 90 %) has occurred before a significant amount of release of the backbone moieties (< 10 %) has taken place. This can be achieved by adjusting the carrier-linked prodrug's half-life versus the degradation kinetics of the hydrogel according to the invention.

Preferentially, a backbone moiety is characterized by having a branching core, from which at least three PEG-based polymeric chains extend. Accordingly, in a preferred aspect of the present invention the backbone reagent comprises a branching core, from which at least three PEG-based polymeric chains extend. Such branching cores may be comprised of poly- or oligoalcohols in bound form, preferably pentaerythritol, tripentaerythritol, hexaglycerine, sucrose, sorbitol, fructose, mannitol, glucose, cellulose, amyloses, starches, hydroxyalkyl starches, polyvinylalcohols, dextrans, hyaluronans, or branching cores may be comprised of poly- or oligoamines such as ornithine,

diaminobutyric acid, trilycine, tetralysine, pentalysine, hexalysine, heptalysine, octalysine, nonalysine, decalysine, undecalysine, dodecalysine, tridecalysine, tetradecalysine, pentadecalysine or oligolysines, polyethyleneimines, polyvinylamines in bound form.

5

Preferably, the branching core extends three to sixteen PEG-based polymeric chains, more preferably four to eight. Preferred branching cores may be comprised of pentaerythritol, ornithine, diaminobutyric acid, trilycine, tetralysine, pentalysine, hexalysine, heptalysine or oligolysine, low-molecular weight PEI, hexaglycerine, tripentaerythritol in bound form. Preferably, the branching core extends three to sixteen PEG-based polymeric chains, more preferably four to eight. Preferably, a PEG-based polymeric chain is a linear poly(ethylene glycol) chain, of which one end is connected to the branching core and the other to a hyperbranched dendritic moiety. It is understood that a polymeric PEG-based chain may be terminated or interrupted by alkyl or aryl groups optionally substituted with heteroatoms and chemical functional groups.

15

Preferably, a PEG-based polymeric chain is a suitably substituted poly(ethylene glycol) derivative (PEG based).

20

25

30

Preferred structures for corresponding PEG-based polymeric chains extending from a branching core contained in a backbone moiety are multi-arm PEG derivatives as, for instance, detailed in the products list of JenKem Technology, USA (accessed by download from www.jenkemusa.com on July 28, 2009), 4ARM-PEG Derivatives (pentaerythritol core), 8ARM-PEG Derivatives (hexaglycerin core) and 8ARM-PEG Derivatives (tripentaerythritol core). Most preferred are 4arm PEG Amine (pentaerythritol core) and 4arm PEG Carboxyl (pentaerythritol core), 8arm PEG Amine (hexaglycerin core), 8arm PEG Carboxyl (hexaglycerin core), 8arm PEG Amine (tripentaerythritol core) and 8arm PEG Carboxyl (tripentaerythritol core). Preferred molecular weights for such multi-arm PEG-derivatives in a backbone moiety are 1 kDa to 20 kDa, more preferably 1 kDa to 15 kDa and even more preferably 1 kDa to 10 kDa.

It is understood that the terminal amine groups of the above mentioned multi-arm molecules are present in bound form in the backbone moiety to provide further interconnected functional groups and reactive functional groups of a backbone moiety.

It is preferred that the sum of interconnected functional groups and reactive functional groups of a backbone moiety is equally divided by the number of PEG-based polymeric chains extending from the branching core. If the number of PEG-based polymeric chains extending from the branching core does not allow for an equal distribution, it is preferred that the deviation from the mean number of the sum of interconnected and reactive functional groups per PEG-based polymeric chain is kept to a minimum.

More preferably, the sum of interconnected and reactive functional groups of a backbone moiety is equally divided by the number of PEG-based polymeric chains extending from the branching core. For instance, if there are 32 interconnected functional groups and reactive functional groups, eight groups may be provided by each of the four PEG-based polymeric chains extending from the core, preferably by means of dendritic moieties attached to the terminus of each PEG-based polymeric chain.

Alternatively, four groups may be provided by each of eight PEG-based polymeric chains extending from the core or two groups by each of sixteen PEG-based polymeric chains.

Such additional functional groups may be provided by dendritic moieties. Preferably, each dendritic moiety has a molecular weight in the range of from 0.4 kDa to 4 kDa, more preferably 0.4 kDa to 2 kDa. Preferably, each dendritic moiety has at least 3 branchings and at least 4 reactive functional groups, and at most 63 branchings and 64 reactive functional groups, preferred at least 7 branchings and at least 8 reactive functional groups and at most 31 branchings and 32 reactive functional groups.

Examples for such dendritic moieties are comprised of trilylsine, tetralysine, pentalysine, hexalysine, heptalysine, octalysine, nonalysine, decalysine, undecalysine, dodecalysine, tridecalysine, tetradecalysine, pentadecalysine, hexadecalysine, heptadecalysine, octadecalysine, nonadecalysine in bound form. Examples for such preferred dendritic moieties are comprised of trilylsine, tetralysine, pentalysine, hexalysine, heptalysine in bound form, most preferred trilylsine, pentalysine or heptalysine, ornithine, diaminobutyric acid in bound form.

Most preferably, the hydrogel carrier of the present invention is characterized in that the backbone moiety has a quarternary carbon of formula $C(A-Hyp)_4$, wherein each A is

independently a poly(ethylene glycol) based polymeric chain terminally attached to the quaternary carbon by a permanent covalent bond and the distal end of the PEG-based polymeric chain is covalently bound to a dendritic moiety Hyp, each dendritic moiety Hyp having at least four functional groups representing the interconnected functional groups and reactive functional groups.

Preferably, each A is independently selected from the formula $-(CH_2)_{n1}(OCH_2CH_2)_nX-$, wherein $n1$ is 1 or 2; n is an integer in the range of from 5 to 50; and X is a chemical functional group covalently linking A and Hyp.


Preferably, A and Hyp are covalently linked by an amide linkage.

Preferably, the dendritic moiety Hyp is a hyperbranched polypeptide. Preferably, the hyperbranched polypeptide comprises lysine in bound form. Preferably, each dendritic moiety Hyp has a molecular weight in the range of from 0.4 kDa to 4 kDa. It is understood that a backbone moiety $C(A-Hyp)_4$ can consist of the same or different dendritic moieties Hyp and that each Hyp can be chosen independently. Each moiety Hyp consists of between 5 and 32 lysines, preferably of at least 7 lysines, i.e. each moiety Hyp is comprised of between 5 and 32 lysines in bound form, preferably of at least 7 lysines in bound form. Most preferably, Hyp is comprised of heptalysinyl.

The reaction of polymerizable functional groups a backbone reagent, more specifically of Hyp with the polymerizable functional groups of poly(ethylene glycol) based crosslinker reagents results in a permanent amide bond.

Preferably, $C(A-Hyp)_4$ has a molecular weight in the range of from 1 kDa to 20 kDa, more preferably 1 kDa to 15 kDa and even more preferably 1 kDa to 10 kDa.

One preferred backbone moiety is shown below, dashed lines indicate interconnecting biodegradable linkages to crosslinker moieties and n is an integer of from 5 to 50:



Biodegradability of the hydrogels according to the present invention is achieved by introduction of hydrolytically degradable bonds.

- 5 The terms “hydrolytically degradable”, “biodegradable” or “hydrolytically cleavable”, “auto-cleavable”, or “self-cleavage”, “self-cleavable”, “transient” or “temporary” refers within the context of the present invention to bonds and linkages which are non-enzymatically hydrolytically degradable or cleavable under physiological conditions (aqueous buffer at pH 7.4, 37°C) with half-lives ranging from one hour to three months,
- 10 including, but are not limited to, aconityls, acetals, amides, carboxylic anhydrides, esters, imines, hydrazones, maleamic acid amides, ortho esters, phosphamides, phosphoesters, phosphosilyl esters, silyl esters, sulfonic esters, aromatic carbamates, combinations thereof, and the like.
- 15 If present in a hydrogel according to the invention as degradable interconnected functional group, preferred biodegradable linkages are carboxylic esters, carbonates, phosphoesters and sulfonic acid esters and most preferred are carboxylic esters or carbonates.

Permanent linkages are non-enzymatically hydrolytically degradable under physiological conditions (aqueous buffer at pH 7.4, 37°C) with half-lives of six months or longer, such as, for example, amides.

- 5 To introduce the hydrolytically cleavable bonds into the hydrogel carrier of the invention, the backbone moieties can be directly linked to each other by means of biodegradable bonds.

In one embodiment, the backbone moieties of the biodegradable hydrogel carrier may
10 be linked together directly, i.e. without crosslinker moieties. The hyperbranched dendritic moieties of two backbone moieties of such biodegradable hydrogel may either be directly linked through an interconnected functional group that connects the two hyperbranched dendritic moieties. Alternatively, two hyperbranched dendritic moieties of two different backbone moieties may be interconnected through two spacer moieties
15 connected to a backbone moiety and on the other side connected to a crosslinking moiety separated by an interconnected functional groups.

Alternatively, backbone moieties may be linked together through crosslinker moieties, each crosslinker moiety is terminated by at least two of the hydrolytically degradable
20 bonds. In addition to the terminating degradable bonds, the crosslinker moieties may contain further biodegradable bonds. Thus, each end of the crosslinker moiety linked to a backbone moiety comprises a hydrolytically degradable bond, and additional biodegradable bonds may optionally be present in the crosslinker moiety.

- 25 Preferably, the biodegradable hydrogel carrier is composed of backbone moieties interconnected by hydrolytically degradable bonds and the backbone moieties are linked together through crosslinker moieties.

The biodegradable hydrogel carrier may contain one or more different types of
30 crosslinker moieties, preferably one. The crosslinker moiety may be a linear or branched molecule and preferably is a linear molecule. In a preferred embodiment of the invention, the crosslinker moiety is connected to backbone moieties by at least two biodegradable bonds.

Preferably, crosslinker moieties have a molecular weight in the range of from 60 Da to 5 kDa, more preferably, from 0.5 kDa to 5 kDa, even more preferably from 1 kDa to 4 kDa, even more preferably from 1 kDa to 3 kDa. In one embodiment, a crosslinker moiety consists of a polymer.

5

In addition to oligomeric or polymeric crosslinking moieties, low-molecular weight crosslinking moieties may be used, especially when hydrophilic high-molecular weight backbone moieties are used for the formation of a biodegradable hydrogel according to the invention.

10

Preferably, the poly(ethylene glycol) based crosslinker moieties are hydrocarbon chains comprising ethylene glycol units, optionally comprising further chemical functional groups, wherein the poly(ethylene glycol) based crosslinker moieties comprise at least each m ethylene glycol units, wherein m is an integer in the range of from 3 to 100, preferably from 10 to 70. Preferably, the poly(ethylene glycol) based crosslinker moieties have a molecular weight in the range of from 0.5 kDa to 5 kDa.

15

20

If used in reference to a crosslinker moiety or a PEG-based polymeric chain connected to a branching core, the term "PEG-based" refers to a crosslinker moiety or PEG-based polymeric chain comprising at least 20 weight % ethylene glycol moieties.

25

In one embodiment, monomers constituting the polymeric crosslinker moieties are connected by biodegradable bonds. Such polymeric crosslinker moieties may contain up to 100 biodegradable bonds or more, depending on the molecular weight of the crosslinker moiety and the molecular weight of the monomer units. Examples for such crosslinker moieties are poly(lactic acid) or poly(glycolic acid) based polymers. It is understood that such poly(lactic acid) or poly(glycolic acid) chain may be terminated or interrupted by alkyl or aryl groups and that they may optionally be substituted with heteroatoms and chemical functional groups.

30

Preferably, the crosslinker moieties are PEG based, preferably represented by only one PEG based molecular chain. Preferably, the poly(ethylene glycol) based crosslinker moieties are hydrocarbon chains comprising ethylene glycol units, optionally comprising further chemical functional groups, wherein the poly(ethylene glycol) based crosslinker

moieties comprise at least each m ethylene glycol units, wherein m is an integer in the range of from 3 to 100, preferably from 10 to 70. Preferably, the poly(ethylene glycol) based crosslinker moieties have a molecular weight in the range of from 0.5 kDa to 5 kDa.

5

In a preferred embodiment of the present invention the crosslinker moiety consists of PEG, which is symmetrically connected through ester bonds to two alpha, omega-aliphatic dicarboxylic spacers provided by backbone moieties connected to the hyperbranched dendritic moiety through permanent amide bonds.

10

The dicarboxylic acids of the spacer moieties connected to a backbone moiety and on the other side is connected to a crosslinking moiety consist of 3 to 12 carbon atoms, most preferably between 5 and 8 carbon atoms and may be substituted at one or more carbon atom. Preferred substituents are alkyl groups, hydroxyl groups or amido groups or substituted amino groups. One or more of the aliphatic dicarboxylic acid's methylene groups may optionally be substituted by O or NH or alkyl-substituted N. Preferred alkyl is linear or branched alkyl with 1 to 6 carbon atoms.


15

20

Preferably, there is a permanent amide bond between the hyperbranched dendritic moiety and the spacer moiety connected to a backbone moiety and on the other side is connected to a crosslinking moiety.

One preferred crosslinker moiety is shown below; dashed lines indicate interconnecting biodegradable linkages to backbone moieties:

25




wherein q is an integer of from 5 to 50.

Preferably, the hydrogel carrier is composed of backbone moieties interconnected by hydrolytically degradable bonds.


30

More preferably, the backbone moieties comprise a branching core of the following formula:



wherein the dashed line indicates attachment to the remainder of the backbone moiety.


More preferably, the backbone moieties comprise a structure of the following formula:



wherein n is an integer of from 5 to 50 and the dashed line indicates attachment to the remainder of the backbone moiety.


Preferably, backbone moiety comprises a hyperbranched moiety Hyp.

More preferably, the backbone moiety comprises a hyperbranched moiety Hyp of the following formula:



wherein the dashed lines indicate attachment to the rest of the molecule and carbon atoms marked with asterisks indicate S-configuration.


Preferably, the backbone moieties are attached to at least one spacer of the following formula:



wherein one of the dashed lines indicates attachment to the hyperbranched moiety Hyp and the second dashed line indicates attachment to the rest of the molecule; and

5 wherein m is an integer of from 2 to 4.

Preferably, the backbone moieties are linked together through crosslinker moieties having the following structure



10 wherein

q is an integer from 3 to 100, preferably from 5 to 50.

In hydrogel prodrugs of the invention, the hydrolysis rate of the biodegradable bonds between backbone moieties and crosslinker moieties is influenced or determined by the number and type of connected atoms adjacent to the PEG-ester carboxy group. For instance, by selecting from succinic, adipic or glutaric acid for PEG ester formation it is possible to vary the degradation half-lives of the biodegradable hydrogel carrier according to the invention.

20 Preferably, L^2 is attached to Z through a thiosuccinimide group which in turn is attached to the hydrogel's backbone moiety through a spacer, such as an oligoethylene glycol chain. Preferably, the linkage of this spacer chain to the backbone moiety is a permanent bond, preferably an amide bond.

25 Biodegradability of the hydrogels according to the present invention is achieved by introduction of hydrolytically degradable bonds.

For interconnected functional groups, the term "hydrolytically degradable" refers within the context of the present invention to linkages which are non-enzymatically hydrolytically degradable under physiological conditions (aqueous buffer at pH 7.4, 30 37°C) with half-lives ranging from one hour to three months, include, but are not limited

to, aconityls, acetals, carboxylic anhydrides, esters, imines, hydrazones, maleamic acid amides, ortho esters, phosphamides, phosphoesters, phosphosilyl esters, silyl esters, sulfonic esters, aromatic carbamates, combinations thereof, and the like. Preferred biodegradable linkages are carboxylic esters, carbonates, phosphoesters and sulfonic acid esters and most preferred are carboxylic esters or carbonates. It is understood that for in vitro studies accelerated conditions like, for example, pH 9, 37°C, aqueous buffer, may be used for practical purposes.

Permanent linkages are non-enzymatically hydrolytically degradable under physiological conditions (aqueous buffer at pH 7.4, 37°C) with half-lives of six months or longer, such as, for example, amides.

The degradation of the biodegradable hydrogel carrier according to the invention is a multi-step reaction where a multitude of degradable bonds is cleaved resulting in degradation products which may be water-soluble or water-insoluble. However, water-insoluble degradation products may further comprise degradable bonds so that they can be cleaved in that water-soluble degradation products are obtained. These water-soluble degradation products may comprise one or more backbone moieties. It is understood that released backbone moieties may, for instance, be permanently conjugated to spacer or blocking or linker groups or affinity groups and/or prodrug linker degradation products and that also water-soluble degradation products may comprise degradable bonds.

The structures of the branching core, PEG-based polymeric chains, hyperbranched dendritic moieties and moieties attached to the hyperbranched dendritic moieties can be inferred from the corresponding descriptions provided in the sections covering the hydrogel carriers of the present invention. It is understood that the structure of a degradant depends on the type of hydrogel according to the invention undergoing degradation.

The total amount of backbone moieties can be measured in solution after complete degradation of the hydrogel according to the invention, and during degradation, fractions of soluble backbone degradation products can be separated from the insoluble hydrogel according to the invention and can be quantified without interference from

other soluble degradation products released from the hydrogel according to the invention. A hydrogel object according to the invention may be separated from excess water of buffer of physiological osmolality by sedimentation or centrifugation.


Centrifugation may be performed in such way that the supernatant provides for at least 10% of the volume of the swollen hydrogel according to the invention. Soluble hydrogel degradation products remain in the aqueous supernatant after such sedimentation or centrifugation step, and water-soluble degradation products comprising one or more backbone moieties are detectable by subjecting aliquots of such supernatant to suitable separation and/or analytical methods.

Preferably, water-soluble degradation products may be separated from water-insoluble degradation products by filtration through 0.45 μm filters, after which the water-soluble degradation products can be found in the flow-through. Water-soluble degradation products may also be separated from water-insoluble degradation products by a combination of a centrifugation and a filtration step.

For instance the backbone moieties may carry groups that exhibit UV absorption at wavelengths where other degradation products do not exhibit UV absorption. Such selectively UV-absorbing groups may be structural components of the backbone moiety such as amide bonds or may be introduced into the backbone by attachment to its reactive functional groups by means of aromatic ring systems such as indoyl groups.

In such hydrogel-linked exendin prodrugs according to the invention, it is desirable that almost all exendin release (> 90 %) has occurred before a significant amount of release of the backbone degradation products (< 10 %) has taken place. This can be achieved by adjusting the hydrogel-linked exendin prodrug's half-life versus the hydrogel degradation kinetics.

Preferably, the exendin prodrug D-L has a structure, where L is represented by formula (II)



5 Preferably, the hydrogel in formula (II) is a biodegradable poly(ethylene glycol) (PEG) based water-insoluble hydrogel.

10


$$\text{C} \left[\text{---CH}_2\text{---O---} \right]_4$$

15

$$\text{C} \left[\text{O} \left[\text{CH}_2 \text{CH}_2 \text{O} \right]_n \text{CH}_2 \text{CH}_2 \text{N} \right]_4$$


20

25




wherein the dashed lines indicate attachment to the rest of the molecule and carbon atoms marked with asterisks indicate S-configuration.

- 5 Preferably, the backbone moieties are attached to at least one spacer of the following formula:



- 10 wherein one of the dashed lines indicates attachment to the hyperbranched moiety Hyp and the second dashed line indicates attachment to the rest of the molecule; and wherein m is an integer of from 2 to 4.

Preferably, the backbone moieties are attached to at least one spacer of the following formula:




15 wherein the dashed line marked with the asterisk indicates the bond between the hydrogel and the N of the thiosuccinimide group;

wherein the other dashed line indicates attachment to Hyp; and

wherein p is an integer of from 0 to 10.

5

Preferably, the backbone moieties are linked together through crosslinker moieties having the following structure



wherein q is an integer from 3 to 100.

10

The hydrolysis rate of the biodegradable bonds between backbone and crosslinker moieties is determined by the number and type of connected atoms adjacent to the PEG-ester carboxy group. For instance by selecting from succinic, adipic or glutaric acid for PEG ester formation it is possible to vary the degradation half-lives of the

15

crosslinker.

The hydrogel-linked exendin prodrug of the present invention can be prepared starting from the hydrogel of the present invention by convenient methods known in the art. It is clear to a practitioner in the art that several routes exist. For example the prodrug linker mentioned above to which the biologically active moiety is covalently attached can be reacted with the reactive functional groups of the hydrogel of the present invention with or with already bearing the active moiety in part or as whole.

20

In a preferred method of preparation, the hydrogel is generated through chemical ligation reactions. The hydrogel may be formed from two macromolecular educts with complementary functionalities which undergo a reaction such as a condensation or addition. One of these starting materials is a crosslinker reagent with at least two identical functional groups and the other starting material is a homomultifunctional backbone reagent. Suitable functional groups present on the crosslinker reagent include terminal amino, carboxylic acid and derivatives, maleimide and other alpha,beta unsaturated Michael acceptors like vinylsulfone, thiol, hydroxyl groups. Suitable functional groups present in the backbone reagent include but are not limited to amino,

30

carboxylic acid and derivatives, maleimide and other alpha,beta unsaturated Michael acceptors like vinylsulfone, thiol, hydroxyl groups.

5 If the crosslinker reagent reactive functional groups are used substoichiometrically with respect to backbone reactive functional groups, the resulting hydrogel will be a reactive hydrogel with free reactive functional groups attached to the backbone structure.

10 Optionally, the prodrug linker may be first conjugated to exendin and the resulting exendin-prodrug linker conjugate may then react with the hydrogel's reactive functional groups. Alternatively, after activation of one of the functional groups of the prodrug linker, the linker-hydrogel conjugate may be contacted with exendin in the second reaction step and excess exendin may be removed by filtration after conjugation of the exendin to the hydrogel-bound prodrug linker.


15 A preferred process for the preparation of a prodrug according to the present invention is as follows:

A preferred starting material for the backbone reagent synthesis is a 4-arm PEG tetra amine or 8-arm PEG octa amine, with the PEG reagent having a molecular weight
20 ranging from 2000 to 10000 Dalton, most preferably from 2000 to 5000 Da. To such multi-arm PEG-derivatives, lysine residues are coupled sequentially to form the hyperbranched backbone reagent. It is understood that the lysines can be partially or fully protected by protective groups during the coupling steps and that also the final backbone reagent may contain protective groups. A preferred building block is bis-boc
25 lysine. Alternatively, instead of sequential additions of lysine residues, a dendritic poly-lysine moiety may be assembled first and subsequently coupled to the 4-arm PEG tetra amine or 8-arm PEG octa amine. It is desirable to obtain backbone reagent carrying 32 amino groups, consequently seven lysines would be attached to each arm of a 4-arm PEG, or five lysines would be attached to each arm of a 8-arm PEG. In another
30 embodiment, the multi-arm PEG derivative is a tetra- or octa carboxy PEG. In this case, the dendritic moieties may be generated from glutaric or aspartic acid, and the resulting backbone reagent would carry 32 carboxy groups. It is understood that all or a fraction of the backbone reagent's functional groups may be present in a free form, as salts or conjugated to protecting groups. It is understood that due to practical reasons the


backbone reagent's number of lysines per PEG-arm will be between six and seven, more preferably approximately seven.

A preferred backbone reagent is shown below:

5



Synthesis of the crosslinker reagent starts from a linear PEG chain with a molecular weight ranging from 0.2 to 5 kDa, more preferably from 0.6 to 2 kDa, which is esterified with a half ester of a dicarboxylic acid, such as adipic acid or glutaric acid. Preferred protecting group for half ester formation is the benzylic group. The resulting bis dicarboxylic acid PEG half esters are converted into more reactive carboxy compounds such as acyl chlorides or active esters, e.g. pentafluorophenyl or N-hydroxysuccinimide esters, most preferred N-hydroxysuccinimide esters, of which preferred selected structure is shown below.



Alternatively, the bis dicarboxylic acid PEG half esters may be activated in the presence of a coupling agent such as DCC or HOBt or PyBOP.

In an alternative embodiment, the backbone reagent carries carboxy groups and the corresponding crosslinker reagent would be selected from ester-containing amino-terminated PEG-chains.

5

Backbone reagent and crosslinker reagent may be polymerized to form the hydrogel according to the invention using inverse emulsion polymerization. After selecting the desired stoichiometry between backbone and crosslinker functional groups, backbone and crosslinker are dissolved in DMSO and a suitable emulgator with an appropriately selected HLB value, preferably Arlacel P135, is employed to form an inverse emulsion using a mechanical stirrer and controlling the stirring speed. Polymerization is initiated by the addition of a suitable base, preferably by N,N,N',N'-tetramethylethylene diamine. After stirring for an appropriate amount of time, the reaction is quenched by the addition of an acid, such as acetic acid and water. The beads are harvested, washed, and fractionated according to particle size by mechanical sieving. Optionally, protecting groups may be removed at this stage.

Further, such hydrogel according to the invention may be functionalized with a spacer carrying a different reactive functional group than provided by the hydrogel. For instance maleimide reactive functional groups may be introduced into the hydrogel by coupling a suitable heterobifunctional spacer such as Mal-PEG6-NHS to the hydrogel. Such functionalized hydrogel can be further conjugated to exendin-linker reagents, carrying a reactive thiol group on the linker moiety to form hydrogel-linked exendin prodrugs according to the present invention.

25

After loading the exendin-linker conjugate to the functionalized maleimido group-containing hydrogel, all remaining functional groups are capped with a suitable blocking reagent, such as mercaptoethanol, to prevent undesired side-reactions.

In another preferred embodiment of the invention, an exendin-linker conjugate carrying a free thiol is connected to the linker moiety, is reacted with a maleimide-functionalized hydrogel at temperatures between room temperature and 4°C, more preferred at room temperature, in a buffered aqueous solution of pH 5.5-8, preferably pH 6.5-7.5. Subsequently, the resulting drug-linker-hydrogel conjugate is treated with a low

30

molecular weight compound comprising a thiol group, preferably with a thiol-containing compound of 34-500 Da, most preferably with mercaptoethanol at temperatures between room temperature and 4°C, more preferred at room temperature, in a buffered aqueous solution of pH 5.5-8, preferably pH 6.5-7.5.

5

In another preferred embodiment of the invention, an exendin-linker conjugate carrying a maleimide group is reacted with a thiol-functionalized hydrogel according to the invention at temperatures between room temperature and 4°C, more preferred at room temperature, in a buffered aqueous solution of pH 5.5-8, preferably pH 6.5-7.5.

10 Subsequently, the corresponding resulting drug-linker-hydrogel conjugate is treated with a low molecular weight compound comprising a maleimide group, preferably a maleimide-containing compound of 100-300 Da, e.g. N-ethyl-maleimide, at temperatures between room temperature and 4°C, more preferred at room temperature, in a buffered aqueous solution of pH 5.5-8, preferably 6.5-7.5.

15

Another aspect of the present invention is a process comprising the steps of

- (a) contacting at temperatures between room temperature and 4°C in a buffered aqueous solution of pH 5.5-8 an aqueous suspension comprising maleimide-functionalized hydrogel microparticles with a solution comprising an exendin-linker reagent of the present invention, wherein the chemical functional group of L^{2*} comprises a thiol group, resulting in an exendin-linker-hydrogel conjugate;
- (b) optionally, treating the exendin-linker-hydrogel conjugate from step (a) with a thiol-containing compound of 34 Da to 500 Da at temperatures between room temperature and 4°C in a buffered aqueous solution of pH 5.5-8.

25

Another aspect of the present invention is a process comprising the steps of

- (a) contacting at temperatures between room temperature and 4°C in a buffered aqueous solution of pH 5.5-8 an aqueous suspension comprising thiol-functionalized hydrogel microparticles with a solution comprising an exendin-linker reagent of the present invention, wherein the chemical functional group of L^{2*} comprises a maleimide group, resulting in an exendin-linker-hydrogel conjugate;

30

(b) optionally, treating the exendin-linker-hydrogel conjugate from step (a) with a maleimide-containing compound of 100 to 300 Da at temperatures between room temperature and 4°C in a buffered aqueous solution of pH 5.5-8.

5 A particularly preferred method for the preparation of a prodrug of the present invention comprises the steps of

- 10 (a) reacting a compound of formula $C(A'-X^1)_4$, wherein $A'-X^1$ represents A before its binding to Hyp or a precursor of Hyp and X^1 is a suitable functional group, with a compound of formula $Hyp'-X^2$, wherein $Hyp'-X^2$ represents Hyp before its binding to A or a precursor of Hyp and X^2 is a suitable functional group to react with X^1 ;
- 15 (b) optionally reacting the resulting compound from step (a) in one or more further steps to yield a compound of formula $C(A-Hyp)_4$ having at least four functional groups;
- 20 (c) reacting the at least four functional groups of the resulting compound from step (b) with a poly(ethylene glycol) based crosslinker precursor, wherein the active ester groups of the crosslinker precursor are used in a sub-stoichiometric amount compared to the total number of reactive functional groups of $C(A-Hyp)_4$ to yield a hydrogel;
- 25 (d) reacting remaining un-reacted functional groups (representing the reactive functional groups of the backbone comprised in the hydrogel) in the hydrogel backbone of step (c) with a covalent conjugate of biologically active moiety and transient prodrug linker or first reacting the un-reacted functional groups with the transient prodrug linker and subsequently with the biologically active moiety;
- 30 (e) optionally capping remaining un-reacted functional groups to yield a prodrug of the present invention.

Specifically, hydrogels for the exendin prodrugs of the present invention are synthesized as follows:

For bulk polymerization, backbone reagent and crosslinker reagent are mixed in a ratio amine/active ester of 2:1 to 1.05:1.

- 5 Both backbone reagent and crosslinker reagent are dissolved in DMSO to give a solution with a concentration of 5 to 50 g per 100 mL, preferably 7.5 to 20 g per 100 ml and most preferably 10 to 20 g per 100 ml.

- 10 To effect polymerization, 2 to 10 % (vol.) N,N,N',N'-tertramethylethylene diamine (TMEDA) are added to the DMSO solution containing crosslinker reagent and backbone reagent and the mixture is shaken for 1 to 20 sec and left standing. The mixture solidifies within less than 1 min.

- 15 Such hydrogel according to the invention is preferably comminuted by mechanical processes such as stirring, crushing, cutting pressing, or milling, and optionally sieving.

For emulsion polymerization, the reaction mixture is comprised of the dispersed phase and the continuous phase.

- 20 For the dispersed phase, backbone reagent and crosslinker reagent are mixed in a ratio amine/active ester of 2:1 to 1.05:1 and are dissolved in DMSO to give a to give a solution with a concentration of 5 to 50 g per 100 mL, preferably 7.5 to 20 g per 100 ml and most preferably 10 to 20 g per 100 ml.

- 25 The continuous phase is any solvent, that is not miscible with DMSO, not basic, aprotic and shows a viscosity lower than 10 Pa*s. Preferably, the solvent is not miscible with DMSO, not basic, aprotic, shows a viscosity lower than 2 Pa*s and is non-toxic. More preferably, the solvent is a saturated linear or branched hydrocarbon with 5 to 10 carbon atoms. Most preferably, the solvent is n-heptane.

- 30 To form an emulsion of the dispersed phase in the continuous phase, an emulsifier is added to the continuous phase before adding the dispersed phase. The amount of emulsifier is 2 to 50 mg per mL dispersed phase, more preferably 5 to 20 mg per mL dispersed phase, most preferably 10 mg per mL dispersed phase.


The emulsifier has an HLB-value of 3 to 8. Preferably, the emulsifier is a triester of sorbitol and a fatty acid or an poly(hydroxyl fatty acid)-poly(ethylene glycol) conjugate. More preferably, the emulsifier is an poly(hydroxy-fatty acid)-polyethylene glycol
5 conjugate, with a linear poly(ethylene glycol) of a molecular weight in the range of from 0.5 kDa to 5 kDa and poly(hydroxy-fatty acid) units of a molecular weight in the range of from 0.5 kDa to 3 kDa on each end of the chain. Most preferably, the emulsifier is poly(ethylene glycol) dipolyhydroxy stearate, Cithrol DPHS (Cithrol DPHS, former Arlacel P135, Croda International Plc).

10 Droplets of the dispersed phase are generated by stirring with an axial flow impeller with a geometry similar to stirrers such as Isojet, Intermig, Propeller (EKATO Rühr- und Mischtechnik GmbH, Germany)), most preferably similar to Isojet with a diameter of 50 to 90 % of the reactor diameter. Preferably, stirring is initiated before addition of the
15 dispersed phase. Stirrer speed is set to 0.6 to 1.7 m/s. The dispersed phase is added at room temperature, and the concentration of the disperse phase is 2% to 70%, preferably 5 to 50%, more preferably 10 to 40%, and most preferably 20 to 35% of the total reaction volume. The mixture of dispersed phase, emulsifier and continuous phase is stirred for 5 to 60 min before adding the base to the effect polymerization.

20 5 to 10 equivalents (referred to each amide bond to be formed) of a base are added to the mixture of dispersed and continuous phase. The base is aprotic, non nucleophilic and soluble in the disperse phase. Preferably, the base is aprotic, non nucleophilic, well soluble in both disperse phase and DMSO. More preferably, the base is aprotic, non
25 nucleophilic, well soluble in both disperse phase and DMSO, an amine base and non-toxic. Most preferably, the base is N,N,N',N'-tertramethylethylene diamine (TMEDA). Stirring in the presence of base is continued for 1 to 16 h.

During stirring, droplets of dispersed phase are hardened to become crosslinked
30 hydrogel beads according to the invention which can be collected and fractionation according to size is performed on a vibrational continuous sieving machine with a 75 µm and a 32 µm deck to give hydrogel microparticles according to the invention.

Another aspect of the present invention is an exendin-linker conjugate intermediate D-L', wherein L' is of formula (III)




5 wherein the dashed line indicates the attachment to one of the amino groups of the exendin moiety by forming an amide bond;

Another aspect of the present invention are exendin-linker reagents D-L*, wherein

10

D represents an exendin moiety; and

L* is a non-biologically active linker reagent represented by formula (IV),



15

wherein the dashed line indicates the attachment to one of the amino groups of the exendin by forming an amide bond;

20 R¹ is selected from C₁₋₄ alkyl, preferably CH₃;

R², R^{2a}, are independently selected from the group consisting of H and C₁₋₄ alkyl,

wherein L* is substituted with one L^{2*} and optionally further substituted, provided that
 25 the hydrogens marked with the asterisks in formula (IV) are not replaced by a substituent and wherein

L^{2*} is a spacer connected to L* and comprising a chemical functional group intended for conjugation to a hydrogel.

Preferably, R^2 in formula (IV) is replaced by L^{2*} .

Preferably, R^1 in formula (IV) is CH_2-L^{2*} .

5

Preferably, L^* in formula (IV) is not further substituted.

Preferably, L^{2*} comprises a thiol group.

10 Preferably, L^{2*} comprises a maleimide group.

Preferably, L^{2*} is L^2-H .

15 The hydrogel for the prodrug of the present invention can be obtained from the preparation methods in the form of a shaped article, such as a mesh or a stent or microparticles. Most preferably, the hydrogel is formed into microparticulate beads which can be administered as subcutaneous or intramuscular injection by means of a standard syringe. Such soft beads may have a diameter of between 1 and 500 micrometer.

20

Preferably, the microparticles have a diameter of between 10 and 100 micrometer if suspended in an isotonic aqueous formulation buffer, more preferably a diameter of between 20 and 100 micrometer, most preferably a diameter of between 25 and 80 micrometer.

25

Preferably, the microparticles can be administered by injection through a needle smaller than 0.6 mm inner diameter, preferably through a needle smaller than 0.3 mm inner diameter, more preferably through a needle smaller than 0.225 mm inner diameter, even more preferably through a needle smaller than 0.175 mm inner diameter, and 30 most preferably through a needle small than 0.16 mm inner diameter.

It is understood that the terms "can be administered by injection", "injectable" or "injectability" refer to a combination of factors such as a certain force applied to a plunger of a syringe containing the biodegradable hydrogel according to the invention swollen in a liquid at a certain concentration (w/v) and at a certain temperature, a

needle of a given inner diameter connected to the outlet of such syringe, and the time required to extrude a certain volume of the biodegradable hydrogel according to the invention from the syringe through the needle.

- 5 In order to provide for injectability, a volume of 1 mL of the exendin prodrugs according to the invention swollen in water to a concentration of at least 5% (w/v) and contained in a syringe holding a plunger of a diameter of 4.7 mm can be extruded at room temperature within 10 seconds by applying a force of less than 50 Newton.
- 10 Preferably, injectability is achieved for an exendin prodrug according to the invention swollen in water to a concentration of ca. 10% (w/v).

Another aspect of the present invention is a process for preparing a needle injectable prodrug comprising the step of

- 15 (a) preparing an exendin hydrogel prodrug of the present invention in the form of microparticles;
- (b) sieving the microparticles
- (c) selecting a fraction with a prodrug bead diameter of between 25 and 80 μm .
- 20 (d) suspending the bead fraction of step (c) in an aqueous buffer solution suitable for injection.

Another aspect of the present invention is a needle-injectable prodrug obtainable from the process described above, wherein the needle injectable prodrug is injectable

25 through a needle with an inner diameter of less than 300 μm , preferably through a needle with an inner diameter of less than 225 μm , and more preferably through a needle with an inner diameter of less than 175 μm .

Another aspect of the present invention is a pharmaceutical composition comprising a

30 prodrug of the present invention or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable excipient. The pharmaceutical composition is further described in the following paragraphs.

The composition of exendin-hydrogel prodrug may be provided as a suspension composition or as a dry composition. Preferably, the pharmaceutical composition of exendin-hydrogel prodrug is a dry composition. Suitable methods of drying are, for example, spray-drying and lyophilization (freeze-drying). Preferably, the pharmaceutical composition of exendin-hydrogel prodrug is dried by lyophilization.

Preferably, the exendin hydrogel prodrug is sufficiently dosed in the composition to provide therapeutically effective amount of exendin for at least three days in one application. More preferably, one application of the exendin hydrogel prodrug is sufficient for one week.

The pharmaceutical composition of exendin-hydrogel prodrug according to the present invention contains one or more excipients.

Excipients used in parenteral compositions may be categorized as buffering agents, isotonicity modifiers, preservatives, stabilizers, anti-adsorption agents, oxidation protection agents, viscosifiers/viscosity enhancing agents, or other auxiliary agents. In some cases, these ingredients may have dual or triple functions. The compositions of exendin-hydrogel prodrugs according to the present invention contain one or more than one excipient, selected from the groups consisting of:

- (i) Buffering agents: physiologically tolerated buffers to maintain pH in a desired range, such as sodium phosphate, bicarbonate, succinate, histidine, citrate and acetate, sulphate, nitrate, chloride, pyruvate. Antacids such as $\text{Mg}(\text{OH})_2$ or ZnCO_3 may be also used. Buffering capacity may be adjusted to match the conditions most sensitive to pH stability
- (ii) Isotonicity modifiers: to minimize pain that can result from cell damage due to osmotic pressure differences at the injection depot. Glycerin and sodium chloride are examples. Effective concentrations can be determined by osmometry using an assumed osmolality of 285-315 mOsmol/kg for serum
- (iii) Preservatives and/or antimicrobials: multidose parenteral preparations require the addition of preservatives at a sufficient concentration to minimize risk of patients becoming infected upon injection and corresponding regulatory

requirements have been established. Typical preservatives include m-cresol, phenol, methylparaben, ethylparaben, propylparaben, butylparaben, chlorobutanol, benzyl alcohol, phenylmercuric nitrate, thimerosal, sorbic acid, potassium sorbate, benzoic acid, chlorocresol, and benzalkonium chloride

5

(iv) Stabilizers: Stabilisation is achieved by strengthening of the protein-stabilising forces, by destabilisation of the denatured state, or by direct binding of excipients to the protein. Stabilizers may be amino acids such as alanine, arginine, aspartic acid, glycine, histidine, lysine, proline, sugars such as glucose, sucrose, trehalose, polyols such as glycerol, mannitol, sorbitol, salts such as potassium phosphate, sodium sulphate, chelating agents such as EDTA, hexaphosphate, ligands such as divalent metal ions (zinc, calcium, etc.), other salts or organic molecules such as phenolic derivatives. In addition, oligomers or polymers such as cyclodextrins, dextran, dendrimers, PEG or PVP or protamine or HSA may be used

10

15

(v) Anti-adsorption agents: Mainly ionic or non-ionic surfactants or other proteins or soluble polymers are used to coat or adsorb competitively to the inner surface of the composition's or composition's container. E.g., poloxamer (Pluronic F-68), PEG dodecyl ether (Brij 35), polysorbate 20 and 80, dextran, polyethylene glycol, PEG-polyhistidine, BSA and HSA and gelatines. Chosen concentration and type of excipient depends on the effect to be avoided but typically a monolayer of surfactant is formed at the interface just above the CMC value

20

(vi) Lyo- and/or cryoprotectants: During freeze- or spray drying, excipients may counteract the destabilising effects caused by hydrogen bond breaking and water removal. For this purpose sugars and polyols may be used but corresponding positive effects have also been observed for surfactants, amino acids, non-aqueous solvents, and other peptides. Trehalose is particularly efficient at reducing moisture-induced aggregation and also improves thermal stability potentially caused by exposure of protein hydrophobic groups to water. Mannitol and sucrose may also be used, either as sole lyo/cryoprotectant or in combination with each other where higher ratios of mannitol:sucrose are known to enhance physical stability of a lyophilized cake. Mannitol may also be

25

30

combined with trehalose. Trehalose may also be combined with sorbitol or sorbitol used as the sole protectant. Starch or starch derivatives may also be used

- 5 (vii) Oxidation protection agents: antioxidants such as ascorbic acid, ectoine, methionine, glutathione, monothioglycerol, morin, polyethylenimine (PEI), propyl gallate, vitamin E, chelating agents such as citric acid, EDTA, hexaphosphate, thioglycolic acid
- 10 (viii) Viscosifiers or viscosity enhancers: retard settling of the particles in the vial and syringe and are used in order to facilitate mixing and resuspension of the particles and to make the suspension easier to inject (i.e., low force on the syringe plunger). Suitable viscosifiers or viscosity enhancers are, for example, carbomer viscosifiers like Carbopol 940, Carbopol Ultrez 10, cellulose derivatives
- 15 like hydroxypropylmethylcellulose (hypromellose, HPMC) or diethylaminoethyl cellulose (DEAE or DEAE-C), colloidal magnesium silicate (Veegum) or sodium silicate, hydroxyapatite gel, tricalcium phosphate gel, xanthans, carrageenans like Satia gum UTC 30, aliphatic poly(hydroxy acids), such as poly(D,L- or L-lactic acid) (PLA) and poly(glycolic acid) (PGA) and their copolymers (PLGA),
- 20 terpolymers of D,L-lactide, glycolide and caprolactone, poloxamers, hydrophilic poly(oxyethylene) blocks and hydrophobic poly(oxypropylene) blocks to make up a triblock of poly(oxyethylene)-poly(oxypropylene)-poly(oxyethylene) (e.g. Pluronic®), polyetherester copolymer, such as a polyethylene glycol terephthalate/polybutylene terephthalate copolymer, sucrose acetate isobutyrate
- 25 (SAIB), dextran or derivatives thereof, combinations of dextrans and PEG, polydimethylsiloxane, collagen, chitosan, polyvinyl alcohol (PVA) and derivatives, polyalkylimides, poly (acrylamide-co-diallyldimethyl ammonium (DADMA)), polyvinylpyrrolidone (PVP), glycosaminoglycans (GAGs) such as dermatan sulfate, chondroitin sulfate, keratan sulfate, heparin, heparan sulfate, hyaluronan,
- 30 ABA triblock or AB block copolymers composed of hydrophobic A-blocks, such as polylactide (PLA) or poly(lactide-co-glycolide) (PLGA), and hydrophilic B-blocks, such as polyethylene glycol (PEG) or polyvinyl pyrrolidone. Such block copolymers as well as the abovementioned poloxamers may exhibit reverse thermal gelation behavior (fluid state at room temperature to facilitate

administration and gel state above sol-gel transition temperature at body temperature after injection).

- (ix) Spreading or diffusing agent: modifies the permeability of connective tissue through the hydrolysis of components of the extracellular matrix in the intrastitial space such as but not limited to hyaluronic acid, a polysaccharide found in the intercellular space of connective tissue. A spreading agent such as but not limited to hyaluronidase temporarily decreases the viscosity of the extracellular matrix and promotes diffusion of injected drugs.
- (x) Other auxiliary agents: such as wetting agents, viscosity modifiers, antibiotics, hyaluronidase. Acids and bases such as hydrochloric acid and sodium hydroxide are auxiliary agents necessary for pH adjustment during manufacture

Preferably, the composition of exendin-hydrogel prodrug contains one or more than one viscosifier and/or viscosity modifying agent.

The term "excipient" preferably refers to a diluent, adjuvant, or vehicle with which the therapeutic is administered. Such pharmaceutical excipient can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, including but not limited to peanut oil, soybean oil, mineral oil, sesame oil and the like.

Water is a preferred excipient when the pharmaceutical composition is administered orally. Saline and aqueous dextrose are preferred excipients when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions are preferably employed as liquid excipients for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and excipients such as triglycerides. Oral formulation can include standard excipients such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical excipients are described in "Remington's

Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the therapeutic, preferably in purified form, together with a suitable amount of excipient so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

5

In a general embodiment a pharmaceutical composition of the present invention whether in dry form or as a suspension or in another form may be provided as single or multiple dose composition.

10 In one embodiment of the present invention, the dry composition of exendin-hydrogel prodrug is provided as a single dose, meaning that the container in which it is supplied contains one pharmaceutical dose.

Thus, in another aspect of the present invention the composition is provided as a single
15 dose composition.

Preferably, the suspension composition is a multiple dose composition, meaning that it contains more than one therapeutic dose. Preferably, a multiple dose composition contains at least 2 doses. Such multiple dose composition of exendin-hydrogel can
20 either be used for different patients in need thereof or is intended for use in one patient, wherein the remaining doses are stored after the application of the first dose until needed.

In another aspect of the present invention the composition is comprised in a container.
25 Preferably the container is a dual-chamber syringe. Especially the dry composition according to the present invention is provided in a first chamber of the dual-chamber syringe and reconstitution solution is provided in a second chamber of the dual-chamber syringe.

30 Prior to applying the dry composition of exendin-hydrogel prodrug to a patient in need thereof, the dry composition is reconstituted. Reconstitution can take place in the container in which the dry composition of exendin-hydrogel prodrug is provided, such as in a vial, syringe, dual-chamber syringe, ampoule, and cartridge. Reconstitution is done by adding a predefined amount of reconstitution solution to the dry composition.

Reconstitution solutions are sterile liquids, such as water or buffer, which may contain further additives, such as preservatives and/or antimicrobials. If the exendin-hydrogel prodrug composition is provided as single dose, the reconstitution solution may contain one or more preservative and/or antimicrobial. Preferably, the reconstitution solution is sterile water. If the composition of exendin-hydrogel prodrug is a multiple dose composition, it is preferred that the reconstitution solution contains one or more preservative and/or antimicrobial, such as, for example, benzylalcohol and cresol.

An additional aspect of the present invention relates to the method of administration of a reconstituted exendin hydrogel prodrug composition. The exendin hydrogel prodrug composition can be administered by methods of injection or infusion, including intradermal, subcutaneous, intramuscular, intravenous, intraosseous, and intraperitoneal.

A further aspect is a method of preparing a reconstituted composition comprising a therapeutically effective amount of an exendin hydrogel prodrug, and optionally one or more pharmaceutically acceptable excipients, wherein the exendin is transiently linked to a hydrogel, the method comprising the step of

- contacting the composition of the present invention with a reconstitution solution.

Another aspect is a reconstituted composition comprising a therapeutically effective amount of a exendin hydrogel prodrug, and optionally one or more pharmaceutically acceptable excipients, wherein the exendin is transiently linked to a hydrogel obtainable by the method above.

Another aspect of the present invention is the method of manufacturing a dry composition of exendin-hydrogel prodrug. In one embodiment, such suspension composition is made by

- (i) admixing the exendin-hydrogel prodrug with one or more excipients,
- (ii) transferring amounts equivalent to single or multiple doses into a suitable container,

- (iii) drying the composition in said container, and
- (iv) sealing the container.

Suitable containers are vials, syringes, dual-chamber syringes, ampoules, and
5 cartridges.

Another aspect is a kit of parts. When the administration device is simply a hypodermic syringe then the kit may comprise the syringe, a needle and a container comprising the dry exendin-hydrogel prodrug composition for use with the syringe and a second container comprising the reconstitution solution. In more preferred embodiments, the
10 injection device is other than a simple hypodermic syringe and so the separate container with reconstituted exendin-hydrogel prodrug is adapted to engage with the injection device such that in use the liquid composition in the container is in fluid connection with the outlet of the injection device. Examples of administration devices include but are not limited to hypodermic syringes and pen injector devices. Particularly
15 preferred injection devices are the pen injectors in which case the container is a cartridge, preferably a disposable cartridge.

A preferred kit of parts comprises a needle and a container containing the composition according to the present invention and optionally further containing a reconstitution
20 solution, the container being adapted for use with the needle. Preferably, the container is a dual-chamber syringe.

In another aspect, the invention provides a cartridge containing a composition of exendin-hydrogel prodrug as hereinbefore described for use with a pen injector device.
25 The cartridge may contain a single dose or multiplicity of doses of exendin.

In one embodiment of the present invention the suspension composition of exendin-hydrogel prodrug does not only comprise an exendin-hydrogel prodrug and one or more than one excipients, but also other biologically active agents, either in their free form or
30 as prodrugs. Preferably, such additional one or more biologically active agent is a prodrug, more preferably a hydrogel prodrug. Such biologically active agents include, but are not limited to, compounds of the following classes:

- (i) Sulfonylureas, such as, for example, chlorpropamide, tolazamide, tolbutamide, glyburide, glipizide, glimepiride, glibenclamide, gliclazide and the like;
- 5 (ii) Meglitinides, such as, for example, repaglinide, nateglinide or mitiglinide;
- (iii) Glucagon-like Peptide-1 (GLP-1) and its mimetics, Glucose-insulinotropic peptide (GIP) and its mimetics, Exendin and its mimetics, and Dipeptyl Protease Inhibitors (DPPIV);
- 10 (iv) Biguanides, such as, for example, metformin;
- (v) Thiazolidinediones, such as, for example, rosiglitazone, pioglitazone, troglitazone, isaglitazone (known as MCC-555), 2-[2-[(2R)-4-hexyl-3,4-
- 15 dihydro-3-oxo-2H-1,4-benzoxazin-2-yl]ethoxy]-benzene acetic acid, ciglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 by Dr. Reddy's Research Foundation, especially 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy]phenyl)methyl]-2,4-thiazolidinedione and the like;
- 20 (vi) GW2570, and the like;
- (vii) Retinoid-X receptor (RXR) modulators, such as, for example, targretin, 9-cis-retinoic acid, and the like;
- 25 (viii) Other insulin sensitizing agents, such as, for example, INS-1, PTP-1B inhibitors, GSK3 inhibitors, glycogen phosphorylase a inhibitors, fructose-1,6-bisphosphatase inhibitors, and the like;
- (ix) Insulins, including regular or short-acting, intermediate-acting, and long-acting
- 30 insulins, inhaled insulin, insulin derivatives and insulin analogues, such as insulin molecules with minor differences in the natural amino acid sequence;
- (x) Small molecule mimics of insulin, including, but not limited to L-783281, TE-17411, and the like;

(xi) Sodium-dependent glucose transporter 1 and/or 2 (SGLT1, SGLT2) inhibitors, for example KGA-2727, T-1095, T-1095A, SGL-0010, AVE 2268, SAR 7226, SGL-5083, SGL-5085, SGL-5094, ISIS-388626, sergliflozin, dapagliflozin or remogliflozin etabonate, canagliflozin, phlorizin, and the like;

(xii) Amylin agonists which include, but are not limited to pramlintide, and the like;

(xiii) Glucagon antagonists such as AY-279955, and the like.

(xiv) Gut hormones and modulators of gut hormone activity, such as Somatostatin, Oxyntomodulin, Cholecystokinin, Incretins, Ghrelin, PYY₃₋₃₆, and the like.

Insulins as described above may independently be selected from the group consisting of bovine insulins, porcine insulins, and human insulins. More preferably insulin is independently selected from human insulins. An insulin may be selected from unmodified insulins, more particularly from bovine insulins, porcine insulins, and human insulins.

Insulin derivatives are derivatives of a naturally occurring insulin and/or an insulin analog, which are obtained by chemical modification. The chemical modification may consist, for example, in the addition of one or more defined chemical groups onto one or more amino acids.

Insulin analogs which are described in EP 0 214 826, EP 0 375 437, EP 0 678 522, EP 0 885 961, EP 0 419 504, WO 92/00321, German patent applications 10 2008 003 568.8 and 10 2008 003 566.1, and EP-A 0 368 187 may be part of the combinations of the invention. The documents EP 0 214 826, EP 0 375 437, EP 0 678 522, EP 0 419 504, WO 92/00321, and EP-A 0 368 187 are included herein by reference.

One preferred insulin analog may be selected from the group consisting of Gly(A21)-Arg(B31)-Arg(B32) human insulin (insulin glargine, Lantus); Arg(A0)-His(A8)-Glu(A15)-Asp(A18)-Gly(A21)-Arg(B31)-Arg(B32) human insulin amide, Lys(B3)-Glu(B29) human insulin; Lys^{B28}Pro^{B29} human insulin (insulin lyspro), B28 Asp human insulin (insulin

aspart), human insulin in which proline in position B28 has been substituted by Asp, Lys, Leu, Val or Ala and where Lys in position B29 may be substituted by Pro; AlaB26 human insulin; des(B28-B30) human insulin; des(B27) human insulin or B29Lys(ϵ -tetradecanoyl), des(B30) human insulin (insulin detemir).

- 5 A preferred insulin derivative may be selected from the group consisting of B29-N-myristoyl-des(B30) human insulin, B29-N-palmitoyl-des(B30) human insulin, B29-N-myristoyl human insulin, B29-N-palmitoyl human insulin, B28-N-myristoyl Lys^{B28}Pro^{B29} human insulin, B28-N-palmitoyl-Lys^{B28}Pro^{B29} human insulin, B30-N-myristoyl-Thr^{B29}Lys^{B30} human insulin, B30-N-palmitoyl-Thr^{B29}Lys^{B30} human insulin, B29-N-(N-palmitoyl-Y-glutamyl)-des(B30) human insulin, B29-N-(N-lithocholyl-Y-glutamyl)-des(B30) human insulin, B29-N-(ω -carboxyheptadecanoyl)-des(B30) human insulin, and B29-N-(ω -carboxyheptadecanoyl) human insulin.

- A more highly preferred insulin derivative is selected from the group consisting of Gly(A21)-Arg(B31)-Arg(B32) human insulin, Lys^{B28}Pro^{B29} human insulin (insulin lyspro), B28 Asp human insulin (insulin aspart), B29Lys(ϵ -tetradecanoyl), desB30 human insulin (insulin detemir).

Preferably, such additional one or more biologically active agent is a hydrogel prodrug of an insulin as described in WO2011/012718 and WO2011/012719.

- 20 In addition to antidiabetic agents, bioactive compounds may be anti-obesity agents such as orlistat, a pancreatic lipase inhibitor, which prevents the breakdown and absorption of fat; or sibutramine, an appetite suppressant and inhibitor of the reuptake of serotonin, norepinephrine and dopamine in the brain, growth factors increasing fat mobilization (eg, growth hormone, IGF-1, growth hormone releasing factor), oxyntomodulin and ghrelin modulators. Other potential bioactive anti-obesity agents include, but are not limited to, appetite-suppressants acting through adrenergic mechanisms such as benzphetamine, phenmetrazine, phentermine, diethylpropion, mazindol, sibutramine, phenylpropanolamine or, ephedrine; appetite-suppressant agents acting through serotonergic mechanisms such as quipazine, fluoxetine, sertraline, fenfluramine, or dextfenfluramine; appetite-suppressant agents acting through dopamine mechanisms, eg, apomorphine; appetite-suppressant agents acting through histaminergic mechanisms (eg, histamine mimetics, H3 receptor modulators); enhancers of energy expenditure such as beta-3 adrenergic agonists and stimulators of uncoupling protein function; leptin and leptin mimetics (eg, metreleptin); neuropeptide Y antagonists;

melanocortin-1, 3 and 4 receptor modulators; cholecystokinin agonists; glucagon-like peptide-1 (GLP-1) mimetics and analogues (eg, Exendin); androgens (eg, dehydroepiandrosterone and derivatives such as etiocholandione), testosterone, anabolic steroids (eg, oxandrolone), and steroidal hormones; galanin receptor antagonists; cytokine agents such as ciliary neurotrophic factor; amylase inhibitors; enterostatin agonists/mimetics; orexin/hypocretin antagonists; urocortin antagonists; bombesin agonists; modulators of protein kinase A; corticotropin-releasing factor mimetics; cocaine- and amphetamine-regulated transcript mimetics; calcitonin-gene related peptide mimetics; and fatty acid synthase inhibitors.

In an alternative embodiment, the exendin-hydrogel prodrug composition according to the present invention is combined with a second biologically active compound in such way that the exendin-hydrogel prodrug is administered to a patient in need thereof first, followed by the administration of the second compound. Alternatively, the exendin-hydrogel composition is administered to a patient in need thereof after another compound has been administered to the same patient.

Yet another aspect of the present invention is a prodrug of the present invention or a pharmaceutical composition of the present invention for use as a medicament.

Yet another aspect of the present invention is a prodrug of the present invention or a pharmaceutical composition of the present invention for use in a method of treating or preventing diseases or disorders which can be treated by exendin. Said compositions are for use in a method of treating or preventing diseases or disorders known for exendin and exendin agonists, for example, for treatment and prevention of hyperglycemia and for treatment and prevention of diabetes mellitus of any type, e.g. insulin-dependent diabetes mellitus, non insulin dependent diabetes mellitus, prediabetes or gestational diabetes mellitus, for prevention and treatment of metabolic syndrome and/or obesity and/or eating disorders, insulin resistance syndrome, lowering plasma lipid level, reducing the cardiac risk, reducing the appetite, reducing the body weight, etc.

Patients in need of treatment with the long acting exendin compositions described in the present invention are at high risk of developing comorbidities. Accordingly, the combination of the long acting exendin of the present with appropriate bioactive

compounds may be used, e.g., for the prevention, delay of progression or treatment of diseases and disorders selected from the group consisting of hypertension (including but not limited to isolated systolic hypertension and familial dyslipidemic hypertension), congestive heart failure, left ventricular hypertrophy, peripheral arterial disease, diabetic retinopathy, macular degeneration, cataract, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, syndrome X, premenstrual syndrome, coronary heart disease, angina pectoris, thrombosis, atherosclerosis, myocardial infarction, transient ischemic attacks, stroke, vascular restenosis, hyperglycemia, hyperinsulinemia, hyperlipidemia, hypertriglyceridemia insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance, conditions of impaired fasting plasma glucose, obesity, erectile dysfunction, skin and connective tissue disorders, foot ulcerations and ulcerative colitis, endothelial dysfunction and impaired vascular compliance.

Prevention, delay of progression or treatment of diseases and disorders selected from the group above can be achieved by combination of the long acting exendin composition of the present invention with at least one bioactive compound selected from the drug classes used for treating said conditions, including AT₁-receptor antagonists; angiotensin converting enzyme (ACE) inhibitors; renin inhibitors; beta adrenergic receptor blockers; alpha adrenergic receptor blockers; calcium channel blockers; aldosterone synthase inhibitors; aldosterone receptor antagonists; neutral endopeptidase (NEP) inhibitors; dual angiotensin converting enzyme/neutral endopeptidase (ACE/NEP) inhibitors; an endothelin receptor antagonists; diuretics; statins; nitrates; anti clotting agents; natriuretic peptides; digitalis compounds; PPAR modulators.

In case the biologically active agents; prodrugs, especially hydrogel prodrugs contain one or more acidic or basic groups, the invention also comprises their corresponding pharmaceutically or toxicologically acceptable salts, in particular their pharmaceutically utilizable salts. Thus, the prodrugs which contain acidic groups can be used according to the invention, for example, as alkali metal salts, alkaline earth metal salts or as ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids. Prodrugs which

contain one or more basic groups, i.e. groups which can be protonated, can be present and can be used according to the invention in the form of their addition salts with inorganic or organic acids. Examples for suitable acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to the person skilled in the art. If the prodrugs simultaneously contain acidic and basic groups in the molecule, the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions). The respective salts can be obtained by customary methods which are known to the person skilled in the art like, for example by contacting these with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts. The present invention also includes all salts of the prodrugs which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.

The term "pharmaceutically acceptable" means approved by a regulatory agency such as the EMEA (Europe) and/or the FDA (US) and/or any other national regulatory agency for use in animals, preferably in humans.

Yet another aspect of the present invention is a method of treating, controlling, delaying or preventing in a mammalian patient, preferably in a human, in need of the treatment of one or more conditions comprising administering to said patient a therapeutically effective amount of a prodrug of the present invention or a pharmaceutical composition of the present invention or a pharmaceutically acceptable salt thereof.

Fig. 1 shows release kinetics of compounds 8, 10, 12, 14 and 16 at pH 7.4, 37°C.

Examples

Materials and Methods

Exendin-4 [Seq ID No:1] on resin (loading approx. 0.1 mmol/g) synthesized by Fmoc strategy was obtained from CASLO Laboratory Aps, Lyngby, Denmark. Lixisenatide [Seq ID No 21] and GLP-1 [Seq ID No 13] on resin (loading approx. 0.1 mmol/g) synthesized by Fmoc strategy was obtained from Peptide Specialty Laboratories, Heidelberg, Germany. The peptides were fully side chain protected and had a free N-Terminus.

Amino 4-arm PEG 5kDa was obtained from JenKem Technology, Beijing, P. R. China. N-(3-maleimidopropyl)-21-amino-4,7,10,13,16,19-hexaoxa-heneicosanoic acid NHS ester (Mal-PEG6-NHS) was obtained from Celares GmbH, Berlin, Germany. 6-(S-Tritylmercapto)hexanoic acid was purchased from Polypeptide, Strasbourg, France. Amino acids used were of L configuration if not stated otherwise. All other chemicals were from Sigma-ALDRICH Chemie GmbH, Taufkirchen, Germany.

Fmoc deprotection:

For Fmoc protecting-group removal, the resin was agitated with 2/2/96 (v/v/v) piperidine/DBU/DMF (two times, 10 min each) and washed with DMF (ten times).

RP-HPLC purification:

RP-HPLC was done on a 100x20 mm or 100x40 mm C18 ReproSil-Pur 300 ODS-3 5µm column (Dr. Maisch, Ammerbuch, Germany) connected to a Waters 600 HPLC System and Waters 2487 Absorbance detector unless otherwise stated. Linear gradients of solution A (0.1% TFA in H₂O) and solution B (0.1% TFA in acetonitrile) were used. HPLC fractions containing product were pooled and lyophilized.

Flash Chromatography

Flash chromatography purifications were performed on an Isolera One system from Biotage AB, Sweden, using Biotage KP-Sil silica cartridges and *n*-heptane and ethyl acetate as eluents. Products were detected at 254 nm.

For hydrogel beads, syringes equipped with polyethylene frits were used as reaction vessels or for washing steps.


Analytical ultra-performance LC (UPLC) was performed on a Waters Acquity system
 5 equipped with a Waters BEH300 C18 column (2.1 x 50 mm, 1.7 μ m particle size)
 coupled to a LTQ Orbitrap Discovery mass spectrometer from Thermo Scientific.

MS of PEG products showed a series of $(\text{CH}_2\text{CH}_2\text{O})_n$ moieties due to polydispersity of
 PEG starting materials. For easier interpretation only one single representative m/z
 10 signal is given in the examples.


Peptide content of hydrogel: Peptide content is expressed as % peptide weight in
 relation to hydrogel brutto weight (sum of weight of maleimide functionalized hydrogel
 and peptide linker thiol). Weight of peptide linker thiol in hydrogel (and thus weight of
 15 peptide alone) was determined by consumption of peptide linker thiol during conjugation
 reaction with maleimide functionalized hydrogel. Consumption of peptide linker thiol was
 determined by Ellman test (Ellman, G. L. et al., *Biochem. Pharmacol.*, 1961, 7, 88-95).

Example 1

Synthesis of backbone reagent 1g



Backbone reagent **1g** was synthesized from amino 4-arm PEG5000 **1a** according to following scheme:



- 5 For synthesis of compound **1b**, amino 4-arm PEG5000 **1a** (MW ca. 5200 g/mol, 5.20 g, 1.00 mmol, HCl salt) was dissolved in 20 mL of DMSO (anhydrous). Boc-Lys(Boc)-OH (2.17 g, 6.25 mmol) in 5 mL of DMSO (anhydrous), EDC HCl (1.15 g, 6.00 mmol), HOBT·H₂O (0.96 g, 6.25 mmol), and collidine (5.20 mL, 40 mmol) were added. The reaction mixture was stirred for 30 min at RT.
- 10 The reaction mixture was diluted with 1200 mL of DCM and washed with 600 mL of 0.1 N H₂SO₄ (2 x), brine (1 x), 0.1 M NaOH (2 x), and 1/1 (v/v) brine/water (4 x). Aqueous layers were reextracted with 500 mL of DCM. Organic phases were dried over Na₂SO₄, filtered and evaporated to give 6.3 g of crude product **1b** as colorless oil. Compound **1b** was purified by RP-HPLC.
- 15 Yield 3.85 g (59%) colorless glassy product **1b**.
MS: m/z 1294.4 = [M+5H]⁵⁺ (MW calculated for [M+5H]⁵⁺ = 1294.6).

Compound **1c** was obtained by stirring of 3.40 g of compound **1b** (0.521 mmol) in 5 mL of methanol and 9 mL of 4 N HCl in dioxane at RT for 15 min. Volatiles were removed in vacuo. The product was used in the the next step without further purification.

20 MS: m/z 1151.9 = [M+5H]⁵⁺ (MW calculated for [M+5H]⁵⁺ = 1152.0).

For synthesis of compound **1d**, 3.26 g of compound **1c** (0.54 mmol) were dissolved in 15 mL of DMSO (anhydrous). 2.99 g Boc-Lys(Boc)-OH (8.64 mmol) in 15 mL DMSO

(anhydrous), 1.55 g EDC HCl (8.1 mmol), 1.24 g HOBt·H₂O (8.1 mmol), and 5.62 mL of collidine (43 mmol) were added. The reaction mixture was stirred for 30 min at RT.

Reaction mixture was diluted with 800 mL DCM and washed with 400 mL of 0.1 N H₂SO₄ (2 x), brine (1 x), 0.1 M NaOH (2 x), and 1/1 (v/v) brine/water (4 x). Aqueous

5 layers were reextracted with 800 mL of DCM. Organic phases were dried with Na₂SO₄, filtered and evaporated to give a glassy crude product.

Product was dissolved in DCM and precipitated with cooled (– 18 °C) diethylether. This procedure was repeated twice and the precipitate was dried in vacuo.

Yield: 4.01 g (89%) colorless glassy product **1d**, which was used in the next step

10 without further purification.

MS: m/z 1405.4 = [M+6H]⁶⁺ (MW calculated for [M+6H]⁶⁺ = 1405.4).

Compound **1e** was obtained by stirring a solution of compound **1d** (3.96 g, 0.47 mmol) in 7 mL of methanol and 20 mL of 4 N HCl in dioxane at RT for 15 min. Volatiles were

15 removed in vacuo. The product was used in the the next step without further purification.

MS: m/z 969.6 = [M+7H]⁷⁺ (MW calculated for [M+7H]⁷⁺ = 969.7).

For the synthesis of compound **1f**, compound **1e** (3.55 g, 0.48 mmol) was dissolved in

20 20 mL of DMSO (anhydrous). Boc-Lys(Boc)-OH (5.32 g, 15.4 mmol) in 18.8 mL of DMSO (anhydrous), EDC HCl (2.76 g, 14.4 mmol), HOBt·H₂O (2.20 g, 14.4 mmol), and 10.0 mL of collidine (76.8 mmol) were added. The reaction mixture was stirred for 60 min at RT.

The reaction mixture was diluted with 800 mL of DCM and washed with 400 mL of 0.1 N H₂SO₄ (2 x), brine (1 x), 0.1 M NaOH (2 x), and 1/1 (v/v) brine/water (4 x). Aqueous

25 layers were reextracted with 800 mL of DCM. Organic phases were dried over Na₂SO₄, filtered and evaporated to give crude product **1f** as colorless oil.

Product was dissolved in DCM and precipitated with cooled (– 18 °C) diethylther. This step was repeated twice and the precipitate was dried in vacuo.

30 Yield: 4.72 g (82%) colourless glassy product **1f** which was used in the next step without further purification.

MS: m/z 1505.3 = [M+8H]⁸⁺ (MW calculated for [M+8H]⁸⁺ = 1505.4).

Backbone reagent **1g** was obtained by stirring a solution of compound **1f** (MW ca. 12035 g/mol, 4.72 g, 0,39 mmol) in 20 mL of methanol and 40 mL of 4 N HCl in dioxane at RT for 30 min. Volatiles were removed in vacuo.

Yield: 3.91 g (100 %), glassy product backbone reagent **1g**.

5 MS: m/z 977.2 = $[M+9H]^{9+}$ (MW calculated for $[M+9H]^{9+}$ = 977.4).

Alternative synthetic route for **1g**

For synthesis of compound **1b**, to a suspension of 4-Arm-PEG5000 tetraamine (**1a**) (50.0 g, 10.0 mmol) in 250 mL of *i*PrOH (anhydrous), boc-Lys(boc)-OSu (26.6 g, 60.0 mmol) and DIEA (20.9 mL, 120 mmol) were added at 45 °C and the mixture was stirred for 30 min.

Subsequently, *n*-propylamine (2.48 mL, 30.0 mmol) was added. After 5 min the solution was diluted with 1000 mL of MTBE and stored overnight at -20 °C without stirring.

Approximately 500 mL of the supernatant were decanted and discarded. 300 mL of cold MTBE were added and after 1 min shaking the product was collected by filtration through a glass filter and washed with 500 mL of cold MTBE. The product was dried *in vacuo* for 16 h.

Yield: 65.6 g (74%) **1b** as a white lumpy solid

MS: m/z 937.4 = $[M+7H]^{7+}$ (MW calculated for $[M+7H]^{7+}$ = 937.6).

20 Compound **1c** was obtained by stirring of compound **1b** from the previous step (48.8 g, 7.44 mmol) in 156 mL of 2-propanol at 40 °C. A mixture of 196 mL of 2-propanol and 78.3 mL of acetylchloride was added under stirring within 1-2 min. The solution was stirred at 40 °C for 30 min and cooled to -30 °C overnight without stirring. 100 mL of cold MTBE were added, the suspension was shaken for 1 min and cooled for 1 h at -30 °C. The product was collected by filtration through a glass filter and washed with 200 mL of cold MTBE. The product was dried *in vacuo* for 16 h.

Yield: 38.9 g (86%) **1c** as a white powder

MS: m/z 960.1 = $[M+6H]^{6+}$ (MW calculated for $[M+6H]^{6+}$ = 960.2).

30 For synthesis of compound **1d**, boc-Lys(boc)-OSu (16.7 g, 37.7 mmol) and DIPEA (13.1 mL, 75.4 mmol) were added to a suspension of **1c** from the previous step (19.0 g, 3.14 mmol) in 80 ml 2-propanol at 45 °C and the mixture was stirred for 30 min at 45 °C. Subsequently, *n*-propylamine (1.56 mL, 18.9 mmol) was added. After 5 min the solution

was precipitated with 600 mL of cold MTBE and centrifuged (3000 min⁻¹, 1 min) The precipitate was dried *in vacuo* for 1 h and dissolved in 400 mL THF. 200 mL of diethyl ether were added and the product was cooled to -30 °C for 16 h without stirring. The suspension was filtered through a glass filter and washed with 300 mL cold MTBE. The product was dried *in vacuo* for 16 h.

Yield: 21.0 g (80%) **1d** as a white solid

MS: m/z 1405.4 = [M+6H]⁶⁺ (MW calculated for [M+6H]⁶⁺ = 1405.4).

Compound **1e** was obtained by dissolving compound **1d** from the previous step (15.6 g, 1.86 mmol) in 3 N HCl in methanol (81 mL, 243 mmol) and stirring for 90 min at 40 °C. 200 mL of MeOH and 700 mL of iPrOH were added and the mixture was stored for 2 h at -30 °C. For completeness of crystallization, 100 mL of MTBE were added and the suspension was stored at -30 °C overnight. 250 mL of cold MTBE were added, the suspension was shaken for 1 min and filtered through a glass filter and washed with 100 mL of cold MTBE. The product was dried *in vacuo*.

Yield: 13.2 g (96%) **1e** as a white powder

MS: m/z 679.1 = [M+10H]¹⁰⁺ (MW calculated for [M+10H]¹⁰⁺ = 679.1).

For the synthesis of compound **1f**, boc-Lys(boc)-OSu (11.9 g, 26.8 mmol) and DIPEA (9.34 mL, 53.6 mmol) were added to a suspension of **1e** from the previous step, (8.22 g, 1.12 mmol) in 165 mL 2-propanol at 45 °C and the mixture was stirred for 30 min. Subsequently, *n*-propylamine (1.47 mL, 17.9 mmol) was added. After 5 min the solution was cooled to -18 °C for 2 h, then 165 mL of cold MTBE were added, the suspension was shaken for 1 min and filtered through a glass filter. Subsequently, the filter cake was washed with 4x 200 mL of cold MTBE/iPrOH 4:1 and 1x 200 mL of cold MTBE. The product was dried *in vacuo* for 16 h.

Yield: 12.8 g, MW (90 %) **1f** as a pale yellow lumpy solid

MS: m/z 1505.3 = [M+8H]⁸⁺ (MW calculated for [M+8H]⁸⁺ = 1505.4).

Backbone reagent **1g** was obtained by dissolving 4ArmPEG5kDa(-LysLys₂Lys₄(boc)₈)₄ (**1f**) (15.5 g, 1.29 mmol) in 30 mL of MeOH and cooling to 0 °C. 4 N HCl in dioxane (120 mL, 480 mmol, cooled to 0 °C) was added within 3 min and the ice bath was

removed. After 20 min, 3 N HCl in methanol (200 mL, 600 mmol, cooled to 0 °C) was added within 15 min and the solution was stirred for 10 min at room temperature. The product solution was precipitated with 480 mL of cold MTBE and centrifuged at 3000 rpm for 1 min. The precipitate was dried *in vacuo* for 1 h and redissolved in 90 mL of MeOH, precipitated with 240 mL of cold MTBE and the suspension was centrifuged at 3000 rpm for 1 min. The product **1g** was dried *in vacuo*


Yield: 11.5 g (89 %) as pale yellow flakes.

MS: m/z 1104.9 = $[M+8H]^{8+}$ (MW calculated for $[M+8H]^{8+}$ = 1104.9).

10 Example 2

Synthesis of crosslinker reagent 2d

Crosslinker reagent **2d** was prepared from adipic acid mono benzyl ester (English, Arthur R. et al., *Journal of Medicinal Chemistry*, **1990**, 33(1), 344-347) and PEG2000 according to the following scheme:



A solution of PEG 2000 (**2a**) (11.0 g, 5.5 mmol) and benzyl adipate half-ester (4.8 g, 20.6 mmol) in DCM (90.0 mL) was cooled to 0°C. Dicyclohexylcarbodiimide (4.47 g, 21.7 mmol) was added followed by a catalytic amount of DMAP (5 mg) and the solution was stirred and allowed to reach room temperature overnight (12 h). The flask was stored at +4°C for 5 h. The solid was filtered and the solvent completely removed by distillation in vacuo. The residue was dissolved in 1000 mL 1/1(v/v) diethyl ether/ethyl acetate and stored at RT for 2 hours while a small amount of a flaky solid was formed. The solid was removed by filtration through a pad of Celite®. The solution was stored in a tightly closed flask at -30°C in the freezer for 12 h until crystallisation was complete. The crystalline product was filtered through a glass frit and washed with cooled diethyl ether (-30°C). The filter cake was dried in vacuo.

Yield: 11.6 g (86 %) **2b** as a colorless solid. The product was used without further purification in the next step.

MS: m/z 813.1 = [M+3H]³⁺ (MW calculated for [M+3H]³⁺ = 813.3)

In a 500 mL glass autoclave PEG2000-bis-adipic acid-bis-benzyl ester **2b** (13.3 g, 5.5 mmol) was dissolved in ethyl acetate (180 mL) and 10% Palladium on charcoal (0.4 g) was added. The solution was hydrogenated at 6 bar, 40°C until consumption of hydrogen had ceased (5-12 h). Catalyst was removed by filtration through a pad of Celite® and the solvent was evaporated in vacuo.

Yield: 12.3 g (quantitative) **2c** as yellowish oil. The product was used without further purification in the next step.

MS: m/z 753.1 = [M+3H]³⁺ (MW calculated for [M+3H]³⁺ = 753.2)

A solution of PEG2000-bis-adipic acid half ester **2c** (9.43 g, 4.18 mmol), *N*-hydroxysuccinimide (1.92 g, 16.7 mmol) and dicyclohexylcarbodiimide (3.44 g, 16.7 mmol) in 75 mL of DCM (anhydrous) was stirred over night at room temperature. The reaction mixture was cooled to 0 °C and precipitate was filtered off. DCM was evaporated and the residue was recrystallized from THF.

Yield: 8.73 g (85%) crosslinker reagent **2d** as colorless solid.

MS: m/z 817.8 = [M+3H]³⁺ (MW calculated for [M+3H]³⁺ = 817.9 g/mol).

Example 3

Preparation of hydrogel beads (3) containing free amino groups

5


10

15

20

25

Preparation of maleimide functionalized hydrogel beads (4) and determination of maleimide substitution



Mal-PEG6-NHS

30


DMSO and five times with pH 3.0 succinate (20 mM, 1 mM EDTA, 0.01 % Tween-20). The sample was washed three times with pH 6.0 sodium phosphate (50 mM, 50 mM ethanolamine, 0.01 % Tween-20) and incubated in the same buffer for 1 h at RT. After that the beads were washed five times with pH 3.0 sodium succinate (20 mM, 1 mM
 5 EDTA, 0.01 % Tween-20).

For determination of maleimide content, an aliquot of hydrogel beads **4** was washed three times with water and ethanol each. The sample was lyophilized and weighed out. Another aliquot of hydrogel beads **4** was reacted with excess mercaptoethanol (in 50 mM sodium phosphate buffer, 30 min at RT), and mercaptoethanol consumption was
 10 detected by Ellman test (Ellman, G. L. et al., *Biochem. Pharmacol.*, **1961**, 7, 88-95). Maleimide content was determined to be between 0.10 and 0.13 mmol/g dry hydrogel.

Example 5

15 Synthesis of linker reagent 5c

Linker reagent **5c** was synthesized according to the following scheme:



20 Synthesis of linker reagent intermediate 5a:

m-Methoxytrityl chloride (3 g, 9.71 mmol) was dissolved in DCM (20 mL) and added dropwise to a solution of ethylenediamine (6.5 mL, 97.1 mmol) in DCM (20 mL). After two hours the solution was poured into diethyl ether (300 mL) and washed three times with 30/1 (v/v) brine/0.1 M NaOH solution (50 ml each) and once with brine (50 mL). The
 25 organic phase was dried over Na_2SO_4 and volatiles were removed under reduced

pressure. Mmt-protected intermediate (3.18 g, 9.56 mmol) was used in the next step without further purification.

The Mmt-protected intermediate (3.18 g, 9.56 mmol) was dissolved in anhydrous DCM (30 mL). 6-(S-Tritylmercapto)hexanoic acid (4.48 g, 11.47 mmol), PyBOP (5.67 g, 11.47 mmol) and DIPEA (5.0 mL, 28.68 mmol) were added and the mixture was agitated for 30 min at RT. The solution was diluted with diethyl ether (250 mL) and washed three times with 30/1 (v/v) brine/0.1 M NaOH solution (50 mL each) and once with brine (50 mL). The organic phase was dried over Na₂SO₄ and volatiles were removed under reduced pressure. **5a** was purified by flash chromatography.

Yield: 5.69 g (8.09 mmol).

MS: m/z 705.4 = [M+H]⁺ (MW calculated = 705.0).

Synthesis of linker reagent intermediate **5b**:

To a solution of **5a** (3.19 g, 4.53 mmol) in anhydrous THF (50 mL) was added BH₃·THF (1 M solution, 8.5 mL, 8.5 mmol) and the solution was stirred for 16 h at RT. Further BH₃·THF (1 M solution, 14 mL, 14 mmol) was added and stirred for 16 h at RT. The reaction was quenched by addition of methanol (8.5 mL). *N,N*-dimethyl-ethylenediamine (3 mL, 27.2 mmol) was added and the solution was heated to reflux and stirred for three h. Reaction mixture was allowed to cool down to RT and was then diluted with ethyl acetate (300 mL), washed with saturated, aqueous Na₂CO₃ solution (2 x 100 mL) and saturated, aqueous NaHCO₃ solution (2 x 100 mL). The organic phase was dried over Na₂SO₄ and volatiles were removed under reduced pressure to obtain crude amine intermediate (3.22 g).

The amine intermediate (3.22 g) was dissolved in DCM (5 mL). Boc₂O (2.97 g, 13.69 mmol) dissolved in DCM (5 mL) and DIPEA (3.95 mL, 22.65 mmol) were added and the mixture was agitated at RT for 30 min. The mixture was purified by flash chromatography to obtain the crude Boc- and Mmt-protected intermediate (3.00 g).

MS: m/z 791.4 = [M+H]⁺, 519.3 = [M-Mmt+H]⁺ (MW calculated = 791.1).

0.4 M aqueous HCl (48 mL) was added to a solution of the Boc- and Mmt-protected intermediate in acetonitrile (45 mL). The mixture was diluted with acetonitrile (10 mL) and stirred for 1 h at RT. Subsequently, the pH value of the reaction mixture was

adjusted to 5.5 by addition of 5 M NaOH solution. Acetonitrile was removed under reduced pressure and the aqueous solution was extracted with DCM (4 x 100 mL). The combined organic phases were dried over Na₂SO₄ and volatiles were removed under reduced pressure. Crude **5b** was used in the next step without further purification.

5 Yield: 2.52 g (3.19 mmol).

MS: m/z 519.3 = [M+H]⁺ (MW calculated = 519.8 g/mol).

Synthesis of linker reagent **5c**:

10 Intermediate **5b** (985 mg, 1.9 mmol) and *p*-nitrophenyl chloroformate (330 mg, 2.5 mmol) were dissolved in anhydrous THF (10 mL). DIPEA (0.653 mL, 3.7 mmol) was added and the mixture was stirred for 2 h at RT. The solution was acidified by addition of acetic acid (1 mL). **5c** was purified by RP-HPLC.

Yield: 776 mg, (1.13 mmol).


MS m/z 706.3 = [M+Na]⁺ (MW calculated = 706.3).

15

Example 6

Synthesis of Exendin linker reagent **6d**

Exendin linker reagent **6d** was synthesized according to the following scheme:



Synthesis of Exendin linker reagent intermediate **6a**:

Fully side chain protected exendin-4 with free N-terminus on resin (2.00 g, 0.2 mmol, loading approximately 0.1 mmol/g) was transferred into a 20 mL syringe equipped with a filter frit. 8 mL of anhydrous DMF was drawn into the syringe and the syringe was shaken (600 rpm) for 15 min in order to pre-swell the resin. The solvent was discarded, and a solution of Fmoc-D-alanine-OH (187 mg, 0.6 mmol), PyBOP (312 mg, 0.6 mmol), and DIPEA (174 μL , 1.0 mmol) in anhydrous DMF (4 mL) was drawn into the syringe. The syringe was shaken at RT and 600 rpm for 60 min. The solution was discharged, and the resin was washed ten times with DMF.

Fmoc-deprotection was performed according to "Materials and Methods".

Synthesis of Exendin linker reagent intermediate **6b**:

A solution of **5c** (137 mg, 0.4 mmol) in anhydrous DMF (3 mL) was added to the resin **6a** (0.2 mmol), followed by a solution of DIPEA (80 μL , 0.46 mmol) in anhydrous DMF (4.5 mL), and the reaction mixture was shaken (600 rpm) at 22°C for 15 hours.

The resin was washed ten times with DMF and ten times with DCM and dried *in vacuo*.

Synthesis of Exendin linker reagent intermediate **6c**:

3-Nitro-2-pyridine-sulfonyl chloride (48 mg, 0.25 mmol) was given into a syringe containing **6b** (0.05 mmol, 0.5 g). Anhydrous DCM (4 mL) was drawn into the syringe and the mixture was shaken (600 rpm) at RT. After 2 h the solution was discarded and the resin was washed 14 times with DCM and dried *in vacuo*.

Synthesis of Exendin linker reagent intermediate **6d**:

In a round bottom flask o-cresol (1.5 mL), thioanisole (1.5 mL), DTT (1.125 g), TES (1.125 mL), and water (1.5 mL) were dissolved in TFA (37.5 mL). **6c** (0.15 mmol, 1.5 g) was added to the stirred (250-350 rpm) solution at RT in order to obtain a homogeneous suspension. Stirring was continued for 45 min. The solution was separated from the resin beads by filtration, the beads were washed with TFA twice (2 mL each) and the washing solutions were combined with the filtrate. TFA was removed from the combined solutions in a stream of nitrogen.

Crude **6d** was precipitated from the concentrated solution (approx. 10 mL) by addition of diethyl ether (30 mL) and vigorous shaking. After centrifugation (2 min, 5000 rpm) the supernatant was discarded and the precipitate was washed with diethyl ether twice (20 mL each).

Dried precipitate was dissolved in a solution of TCEP (114 mg, 0.39 mmol) in 30 mL (v/v) acetonitrile/water containing 0.01 % TFA (v/v). Mixture was incubated for 15 hours at RT. **6d** was purified by RP-HPLC as described in Materials and Methods using a 150 x 30 mm Waters XBridge™ BEH300 C18 10 µm column and a flow of 40 mL/min.


Up to 12 mL of the mixture were loaded on the column. The elution was performed using a linear gradient from 5% to 30% solvent B (5 min) followed by a linear gradient from 30% to 35% solvent B (40 min). Fractions containing product **6d** were pooled and lyophilized. Purity: 86 % (215 nm)

Yield: 85.2 mg (19.2 µmol, starting from 2.00 g resin).

MS m/z 1486.7 = [M+3H]³⁺, (MW calculated = 4460.0 g/mol).

Example 7

Synthesis of Exendin linker reagent 7



Exendin linker reagent **7** was synthesized as described for exendin linker reagent **6a-6d**

5 starting from fully side chain protected exendin-4 on resin with free N-terminus (336 mg, 34 μmol), except the use of Fmoc-L-alanine-OH instead of Fmoc-D-alanine-OH.


Reagents were scaled accordingly in order to obtain the same ratios as were used in **6a-6d**.

Yield: 13.4 mg

10 MS: m/z 1487.4 = $[M+3H]^{3+}$ (MW calculated: 4460.0)

Example 8

Synthesis of Exendin linker hydrogel 8



15 242.5 mg maleimide functionalized hydrogel **4** (25.0 μmol maleimido groups), as suspension in pH 3.0 succinate buffer (20 mM, 1 mM EDTA, 0.01% Tween-20) was filled into a syringe equipped with a filter frit. The hydrogel was washed ten times with 1/1 (v/v) acetonitrile/water containing 0.1% TFA (v/v). A solution of Exendin linker reagent **6d** (122.7 mg, 27.5 μmol) in 1/1 (v/v) acetonitrile/water plus 0.1% TFA (3.7 mL)

20 was drawn up and shaken for 2 min at RT to obtain an equilibrated suspension. 334 μL phosphate buffer (pH 7.4, 0.5 M) was added and the syringe was agitated (600 rpm) at RT for 15 min. Consumption of thiol was monitored by Ellman test. The hydrogel was washed 10 times with 1/1 (v/v) acetonitrile/water containing 0.1% TFA (v/v).

25 Mercaptoethanol (47 μL) was dissolved in 1/1 (v/v) acetonitrile/water plus 0.1% TFA (3 mL) and phosphate buffer (0.5 mL, pH 7.4, 0.5 M). The solution was drawn up into the syringe and the sample was agitated (600 rpm) for 1 h at RT. The solution was discarded and the hydrogel was washed ten times with 1/1 (v/v) acetonitrile/water plus

0.1% TFA. After that the hydrogel was washed ten times with succinate buffer (10 mM succinate, 46 g/L mannitol, 0.05% Tween-20, adjusted with Tris to pH 5.0) and stored at 4 °C.

Exendin content of exendin linker hydrogel was determined according to Materials and
5 Methods.

An exendin content of 30 % (weight) was obtained.

Example 9

Release kinetics in vitro


An aliquot of exendin linker hydrogel **8** (0.5 mg exendin) was transferred into a syringe
10 equipped with a filter frit and washed 5 times with pH 7.4 phosphate buffer (60 mM, 3 mM EDTA, 0.01% Tween-20). The hydrogel was suspended in the same buffer and incubated at 37 °C. At defined time points (after 1 - 7 days incubation time each) the supernatant was exchanged and liberated exendin was quantified by RP-HPLC at 215 nm. UV-signals correlating to liberated exendin were integrated and plotted against
15 incubation time.

Curve-fitting software was applied to estimate the corresponding halftime of release.

A first order release kinetics with a half-life of 45 d was obtained (see **Fig. 1**).

20 Example 10

Synthesis of Exendin linker hydrogel 10




Exendin linker hydrogel **10** was synthesized as described for exendin linker hydrogel **8** except for the use of exendin linker thiol **7** instead of exendin linker thiol **6d**.


25 Exendin content of exendin linker hydrogel was determined according to Materials and Methods. An exendin content of 30.5 % (weight) was obtained.

Example 11

Synthesis of lixisenatide linker reagent 11 d



Synthesis scheme:



Synthesis of lixisenatide linker reagent intermediate **11a**:

Fully side chain protected lixisenatide on resin with free N-terminus (300 mg, loading approximately 0.1 mmol/g) was transferred into a 5 mL syringe equipped with a filter frit. 4 mL of anhydrous DMF was drawn into the syringe and the syringe was shaken (600 rpm) for 15 min in order to pre-swell the resin. The solvent was discarded, and a solution of Fmoc-D-alanine-OH (28 mg, 90 μmol), PyBOP (47 mg, 90 μmol), and DIPEA (26 μL , 150 μmol) in anhydrous DMF (2 mL) was drawn into the syringe. The syringe was shaken at RT and 600 rpm for 60 min. The solution was discharged, and the resin was washed ten times with DMF.

Fmoc-deprotection was performed according to "Materials and Methods".

Synthesis of lixisenatide linker reagent intermediate **11b**:

A solution of **5c** (41 mg, 60 μmol) in anhydrous DMF (1.5 mL) was added to the resin **11a** (30 μmol), followed by addition of DIPEA (13 μL , 75 μmol), and the homogenized reaction mixture was shaken (600 rpm) at 22 °C for 22 hours.

The resin was washed ten times with DMF and ten times with DCM and dried *in vacuo*.

Synthesis of lixisenatide linker reagent intermediate **11c**:

3-Nitro-2-pyridine-sulfonyl chloride (38 mg, 0.20 mmol) was given into a syringe equipped with a filter frit, containing **11b**. Anhydrous DCM (2 mL) was drawn into the syringe and
5 the mixture was shaken (600 rpm) at RT. After 3.5 h the solution was discarded and the resin was washed 15 times with DCM and dried *in vacuo*.

Synthesis of lixisenatide linker reagent **11d**:

In 50 mL-Falcon tube NBu₄Br (2.9 mg), thioanisole (58.3 µL), DTT (170 mg), TES (170 µL), and water (113.3 µL) were dissolved in TFA (5.83 mL). **11c** (30 µmol) was
10 added to the stirred (200 rpm) solution at RT in order to obtain a homogeneous suspension. Stirring was continued for 1 h. Beads were filtered off and washed with TFA twice (1 mL each). Washing solutions were combined with the filtrate.


Crude **11d** was precipitated from the filtrate (approx. 10 mL) by addition of cold diethyl ether (-18 °C, 40 mL) and vigorous shaking. The suspension was cooled at -18 °C for
15 further 15 min and centrifuged (2 min, 5000 rpm). The supernatant was discarded and the precipitate was washed with diethyl ether twice (20 mL each) and dried under reduced pressure. Precipitate was dissolved in a solution of TCEP (27 mg, 0.94 µmol) in 2.5 mL 1/1 (v/v) acetonitrile/water containing 0.01 % TFA (v/v). Mixture was incubated for 15 hours at RT. 20 mL water was added and **11d** was purified by RP-HPLC in two
20 runs by using a linear gradient from 5% to 30% solvent B (5 min) followed by a linear gradient from 30% to 35% solvent B (40 min). A 150 x 30 mm Waters XBridge™ BEH300 C18 10 µm column and a flow of 40 mL/min was used. Fractions containing product **11d** were pooled and lyophilized.

Yield 6.1 mg

25 MS: m/z 1284.3 = [M+4H]⁴⁺ (MW calculated = 5131.9).

Example 12

Synthesis of lixisenatide linker hydrogel 12




Lixisenatide linker hydrogel **12** was synthesized as described for exendin linker hydrogel **8** except for the use of lixisenatide linker thiol **11d** instead of exendin linker thiol **6d**.

5

Lixisenatide content of lixisenatide linker hydrogel was determined according to Materials and Methods. A lixisenatide content of 32.4 % was obtained.

Example 13

10 Synthesis of lixisenatide linker reagent 13



Lixisenatide linker reagent **13** was synthesized as described for lixisenatide linker reagent **11a-11d** starting from fully side chain protected lixisenatide on resin with free N-terminus (335 mg, 34 μ mol), except the use of Fmoc-L-alanine-OH instead of Fmoc-D-alanine-OH. Reagents were scaled accordingly in order to obtain same ratios as were used in **11a-11d**.


15

Yield 7.3 mg

MS: m/z 1283.9 = $[M+4H]^{4+}$ (MW calculated = 5131.9).

20 Example 14


Synthesis of lixisenatide linker hydrogel 14



Lixisenatide linker hydrogel **14** was synthesized as described for exendin linker hydrogel **8** except for the use of lixisenatide linker thiol **13** instead of exendin linker thiol **6d**.

- 5 Lixisenatide content of lixisenatide linker hydrogel was determined according to Materials and Methods. A lixisenatide content of 34.5 % (weight) was obtained.

Synthesis of GLP-1 linker reagent **15**




- 10 GLP-1 linker reagent **15** was synthesized as described for lixisenatide linker reagent **11a-11d** except from starting from fully side chain protected GLP-1 on resin with free N-terminus (258 mg, 30 μ mol) instead of exendin on resin. Reagents were scaled accordingly in order to obtain same ratios as were used in **11a-11d**.

Yield 5.0 mg

- 15 MS: m/z 1191.4 = $[M+3H]^{3+}$ (MW calculated = 3571.1).

Example 16

Synthesis of GLP-1 linker hydrogel **16**



- 20 GLP-1 linker hydrogel **16** was synthesized as described for exendin linker hydrogel **8** except for the use of GLP-1 linker thiol **15** instead of exendin linker thiol **6d**.

GLP-1 content of GLP-1 linker hydrogel was determined according to Materials and Methods. A GLP-1 content of 26.3 % (weight) was obtained.

25

Example 17

Release kinetics in vitro

Half life time of release at pH 7.4, 37 °C of exendin from hydrogel **10**, of lixisenatide from hydrogels **12** and **14**, and of GLP-1 from hydrogel **16** was determined as described in Example 9. Release kinetics of compounds **8**, **10**, **12**, **14** and **16** are shown in **Fig. 1**.

Hydrogel	drug	configuration of Ala in linker structure	half life time
10	exendin	L	28 d
12	lixisenatide	D	43 d
14	lixisenatide	L	27 d
16	GLP-1	D	50 d
8	exendin	D	45 d


5

Example 18

Synthesis of linker reagent **18e**

Linker reagent **18e** was synthesized according to the following scheme:

10



Synthesis of linker reagent intermediate **18b** was performed under nitrogen atmosphere. A solution of amine **18a** (1.69 g, 4.5 mmol, for preparation see WO-A 2009/133137) in 30 mL THF (dry, mol. sieve) was cooled to 0 °C. Butyl chloroformate (630 µl, 4.95 mmol) in 3 mL THF (dry, mol. sieve) and DIPEA (980 µl, 5.63 mmol) were

15

added. Mixture was stirred for 10 min at 0 °C, cooling was removed and mixture stirred for further 20 min at RT. 1 M LiAlH₄ in THF (9 mL, 9 mmol) was added and mixture was refluxed for 1.5 h. Reaction was quenched by slowly adding methanol (11 mL) and 100 mL sat. Na/K tartrate solution. Mixture was extracted with ethyl acetate, organic layer
5 was dried over Na₂SO₄ and solvent was evaporated under reduced pressure. Crude product **18b** (1.97 g) was used in the next step without further purification.

MS: m/z 390.2 = [M+H]⁺ (MW calculated = 389.6).

A solution of crude product **18b** (1.97 g), N-(bromoethyl)-phthalimide (1.43 g, 5.63 mmol) and K₂CO₃ (1.24 g, 9.0 mmol) in 120 mL acetonitrile was refluxed for 6 h. 60 mL
10 of a sat. NaHCO₃ solution was added and mixture was extracted 3 x with ethyl acetate. Combined organics were dried (Na₂SO₄) and solvent was removed under reduced pressure. Phthalimide **18c** was purified on silica by using heptane (containing 0.02 % NEt₃) and an ascending amount of ethyl acetate (containing 0.02 % NEt₃) as eluents. Yield: 0.82 g (1.46 mmol)

15 MS: m/z 563.3 = [M+H]⁺ (MW calculated = 562.8).

Phthalimide **18c** (819 mg 1.46 mmol) was dissolved in 35 mL ethanol and hydrazine hydrate (176 µl, 3.64 mmol) was added. Mixture was refluxed for 3 h. Precipitate was filtered off. Solvent was removed under reduced pressure and residue was treated with
20 15 mL dichloromethane. Precipitate was filtered off and dichloromethane was removed under reduced pressure. Residue was purified by RP HPLC. Pooled HPLC fractions were adjusted to pH 7 by adding NaHCO₃ and extracted several times with dichloromethane. Combined organics were dried (Na₂SO₄) and solvent was removed under reduced pressure to yield amine **18d**.

25 Yield: 579 mg (1.34 mmol)


MS: m/z 433.3 = [M+H]⁺ (MW calculated = 432.7).

Para-nitrophenyl chloroformate (483 mg, 2.40 mmol) was dissolved in 10 mL dichloromethane (dry, mol. sieve). A solution of amine **18d** (1.00 g, 2.31 mmol) in 5 mL
30 dichloromethane (dry, mol. sieve) and 1.8 mL of sym-collidine were added and mixture was stirred at room temperature for 40 min. Dichloromethane was removed under reduced pressure, residue was acidified with acetic acid and purified by RP-HPLC to yield para-nitrophenyl carbamate **18e**.

Yield: 339 mg (0.57 mmol)

MS: m/z 598.3 = $[M+H]^+$ (MW calculated = 597.8).

Synthesis of GLP-1 linker reagent **19**



GLP-1 linker reagent **19** was synthesized as described for GLP-1 linker reagent **15** except for the use of linker reagent **18e** instead of linker reagent **5c**, starting from fully side chain protected GLP-1 on resin with free N-terminus (150 mg, 16.5 μ mol).


Reagents were scaled accordingly in order to obtain same ratios as were used in **11a-11d**.

Yield 1.33 mg

MS: m/z 1196.0 = $[M+3H]^{3+}$ (MW calculated = 3585.1).

Example 20

Synthesis of GLP-1 linker hydrogel **20**



GLP-1 linker hydrogel **20** was synthesized as described for exendin linker hydrogel **8** except for the use of GLP-1 linker thiol **19** instead of exendin linker thiol **6d**.

Abbreviations:

AcOH	acetic acid
AcOEt	ethyl acetate
Bn	benzyl

	Boc	t-butyloxycarbonyl
	DBU	1,3-diazabicyclo[5.4.0]undecene
	DCC	<i>N,N</i> -dicyclohexylcarbodiimid
	DCM	dichloromethane
5	DIPEA	diisopropylethylamine
	DMAP	dimethylamino-pyridine
	DMF	<i>N,N</i> -dimethylformamide
	DMSO	dimethylsulfoxide
	DTT	DL dithiotreitol
10	EDC	1-Ethyl-3-(3-dimethylaminopropyl)carbodiimid
	EDTA	ethylenediaminetetraacetic acid
	eq	stoichiometric equivalent
	EtOH	ethanol
	Fmoc	9-fluorenylmethoxycarbonyl
15	HPLC	high performance liquid chromatography
	HOBt	<i>N</i> -hydroxybenzotriazole
	iPrOH	2-propanol
	LCMS	mass spectrometry-coupled liquid chromatography
	Mal	3-maleimido propyl
20	Mal-PEG6-NHS	<i>N</i> -(3-maleimidopropyl)-21-amino-4,7,10,13,16,19-hexaoxa-heneicosanoic acid NHS ester
	Me	methyl
	MeOH	methanol
	Mmt	4-methoxytrityl
25	MS	mass spectrum / mass spectrometry
	MTBE	methyl <i>tert.</i> -butyl ether
	MW	molecular mass
	NHS	<i>N</i> -hydroxy succinimide
	PEG	poly(ethylene glycol)
30	PyBOP	benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate
	Phth	phthalimido
	RP-HPLC	reversed-phase high performance liquid chromatography
	rpm	rounds per minute


	RT	room temperature
	SEC	size exclusion chromatography
	TCEP	tris(2-carboxyethyl)phosphine hydrochloride
	TES	triethylsilane
5	TFA	trifluoroacetic acid
	THF	tetrahydrofuran
	TMEDA	N,N,N',N'-tetramethylethylene diamine
	Tris	tris(hydroxymethyl)aminomethane
	Trt	triphenylmethyl, trityl
10	UPLC	ultra performance liquid chromatography
	V	volume

Claims

1. A prodrug or a pharmaceutically acceptable salt thereof comprising an exendin linker conjugate D-L, wherein

D represents an exendin moiety; and

-L is a non-biologically active linker moiety -L¹ represented by formula (I),



wherein the dashed line indicates attachment to one of the amino groups of the exendin by forming an amide bond;

R¹ is selected from C₁₋₄ alkyl;

R², R^{2a} are independently selected from the group consisting of H and C₁₋₄ alkyl,

wherein L¹ is substituted with one L²-Z and optionally further substituted, provided that the hydrogens marked with the asterisks in formula (I) are not replaced by a substituent and wherein

L² is a single chemical bond or a spacer; and

Z is a hydrogel.


2. The prodrug of claim 1, wherein L¹ is not further substituted.

3. The prodrug of claim 1 or 2, wherein R¹ is -CH₃.

4. The prodrug of any of claims 1 to 3, wherein L² is a C₁₋₂₀ alkyl chain, which is optionally interrupted by one or more groups independently selected from -O-; and C(O)N(R_{3aa}); optionally substituted with one or more groups independently


selected from OH; and C(O)N(R3aaR3aaa); and wherein R3aa, R3aaa are independently selected from the group consisting of H; and C₁₋₄ alkyl.

5. The prodrug of any of claims 1 to 4, wherein L² is attached to Z via a terminal group selected from



5

6. The prodrug of any of claims 1 to 5, wherein L is represented by formula (Ia)



wherein the dashed line indicates attachment to the nitrogen of the exendin by forming an amide bond; and wherein


10

L₂ is a single chemical bond or a spacer,

Z is a hydrogel.

15

7. The prodrug of any of claims 1 to 6, wherein L is represented by formula (II)



(II),

20


wherein the dashed line indicates attachment to the nitrogen of the exendin by forming an amide bond and

Z is a hydrogel.

25


8. The prodrug of any of claims 1 to 7, wherein the hydrogel is a PEG-based hydrogel comprised of backbone moieties.

9. The prodrug of claim 8, wherein the backbone moieties comprise a branching core of the following formula:




wherein the dashed line indicates attachment to the remainder of the backbone moiety.

10. The prodrug of claim 8, wherein the backbone moieties comprise a structure of the following formula:




wherein n is an integer of from 5 to 50 and the dashed line indicates attachment to the rest of the molecule.

11. The prodrug of any of claims 8 to 10, wherein the backbone moiety comprises a hyperbranched moiety Hyp of the following formula:




wherein the dashed lines indicate attachment to the rest of the molecule; and carbon atoms marked with asterisks indicate S-configuration.

12. The prodrug of any of claims 8 to 11, wherein the backbone moieties comprise at least one spacer of the following formula:




- 5 wherein one of the dashed lines indicates attachment to the hyperbranched moiety Hyp and the second dashed line indicates attachment to the rest of the molecule; and
wherein m is an integer of from 2 to 4.

- 10 13. The prodrug of any of claims 8 to 12, wherein the backbone moieties comprise at least one spacer of the following formula:



- wherein the dashed line marked with the asterisk indicates the bond between the hydrogel and the N of the thiosuccinimide group of claim 5;
15 wherein the other dashed line indicates attachment to Hyp; and wherein p is an integer of from 0 to 10.

14. The prodrug of any of claims 8 to 13, wherein the backbone moieties are linked together through crosslinker moieties comprising the following structure



20 wherein q is an integer from 3 to 100.

15. A pharmaceutical composition comprising a prodrug of any of claims 1 to 14 or a pharmaceutical salt thereof together with at least one pharmaceutically acceptable excipient.


16. The prodrug of any of claims 1 to 14 or the pharmaceutical composition of claim 15 for use as a medicament.

17. The prodrug of any of claims 1 to 14 or the pharmaceutical composition of claim 15 for use in a method of treating or preventing diseases or disorders which can be treated by exendin.

5 18. An exendin-linker reagent D-L*, wherein

D represents an exendin moiety; and

-L* is a non-biologically active linker reagent represented by formula (IV),



wherein the dashed line indicates the attachment to one of the amino groups of the exendin by forming an amide bond;

15 R¹ is selected from C₁₋₄ alkyl;


R², R^{2a}, are independently selected from the group consisting of H and C₁₋₄ alkyl,

20 wherein L* is substituted with one L^{2*} and optionally further substituted, provided that the hydrogens marked with the asterisks in formula (IV) are not replaced by a substituent and wherein

L^{2*} is a spacer connected to L* and comprising a chemical functional group intended for conjugation to a hydrogel.

25

19. An exendin-linker conjugate intermediate D-L', wherein L' is of formula (III)



wherein the dashed line indicates the attachment to one of the amino groups of the exendin moiety by forming an amide bond;

D represents an exendin moiety.

5

20. A process for the preparation of a prodrug of any of claims 1 to 14, comprising the steps of

10

(a) contacting at temperatures between room temperature and 4°C in a buffered aqueous solution of pH 5.5-8 an aqueous suspension comprising maleimide-functionalized hydrogel microparticles with a solution comprising the exendin-linker reagent of claim 17, wherein the chemical functional group of L^{2*} comprises a thiol group, resulting in an exendin-linker-hydrogel conjugate;

15

(b) optionally, treating the exendin-linker-hydrogel conjugate from step (a) with a thiol-containing compound of 34 Da to 500 Da at temperatures between room temperature and 4°C in a buffered aqueous solution of pH 5.5-8.

21. A process for the preparation of a prodrug of any of claims 1 to 14, comprising the steps of

20

(a) contacting at temperatures between room temperature and 4°C in a buffered aqueous solution of pH 5.5-8 an aqueous suspension comprising thiol-functionalized hydrogel microparticles with a solution comprising the exendin-linker reagent of claim 18, wherein the chemical functional group of L^{2*} comprises a maleimide group resulting in an exendin-linker-hydrogel conjugate;

25

(b) optionally, treating the exendin-linker-hydrogel conjugate from step (a) with a maleimide-containing compound of 100 to 300 Da at temperatures between room temperature and 4°C in a buffered aqueous solution of pH 5.5-8.

22. A process for preparing a needle injectable prodrug comprising the step of

30

(a) preparing a prodrug of any of claims 1 to 14 in the form of microparticles;
(b) sieving the microparticles
(c) selecting a fraction with a prodrug bead diameter of between 25 and 80

µm.

- (d) suspending the bead fraction of step (c) in an aqueous buffer solution suitable for injection.




Fig. 1

